Vape 10-Q 22 Feb 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Dec. 31, 2015	Feb. 22, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Vape Holdings, Inc.
Entity Central Index Key	1,455,819
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Document Type	10-Q
Document Period End Date	Dec. 31, 2015
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,016
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		213,676,990

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Dec. 31, 2015	Sep. 30, 2015
Current assets:
Cash	$ 47,605	$ 273,904
Accounts receivable	75,156	72,401
Inventory	205,254	194,937
Prepaid inventory	231,912	64,079
Other current assets	43,507	40,679
Deferred financing costs	85,495	107,908
Total current assets	688,929	753,908
Fixed assets, net of accumulated depreciation	119,638	118,327
Trademarks	$ 123,150	123,150
Deferred financing costs, long-term		12,067
TOTAL ASSETS	$ 931,717	1,007,452
Current liabilities:
Accounts payable	202,296	115,938
Accrued expenses	$ 208,181	208,665
Customer deposits		1,275
Convertible notes payable, net of unamortized discount of $375,518 and $369,569, respectively	$ 594,873	$ 305,923
Related party notes payable	15,000
Total current liabilities	1,020,350	$ 631,801
Long term liabilities:
Related party convertible notes payable	300,000
Convertible notes payable, long-term, net of unamortized discount of $19,159 and $507,360, respectively	$ 26,541	$ 458,404
Related party notes payable, long-term		265,000
Other liabilities, long-term		12,235
Warrant liability	$ 4,123	25,025
Total liabilities	$ 1,351,014	$ 1,392,465
Commitments and contingencies
Stockholders' deficit:
Common stock, $0.00001 par value - authorized 1,000,000,000 shares; 183,026,935 issued at December 31, 2015, 182,336,310 outstanding at December 31, 2015, and 19,896,521 issued at September 30, 2015, 19,455,896 outstanding at September 30, 2015	$ 1,823	$ 192
Common stock to be issued	90,000
Additional paid-in capital	27,766,743	$ 26,660,868
Prepaid stock-based compensation	(100,000)
Treasury stock, 1,025,625 and 690,625 shares at December 31, 2015 and September 30, 2015, respectively	(440,101)	$ (435,031)
Accumulated deficit	(27,737,762)	(26,611,042)
Total stockholders' deficit	(419,297)	(385,013)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 931,717	$ 1,007,452
Series A Preferred stock
Stockholders' deficit:
Preferred stock value
Series B Preferred Stock
Stockholders' deficit:
Preferred stock value

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) (Unaudited) - USD ($)	Dec. 31, 2015	Sep. 30, 2015
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock to be issued	183,026,935	19,896,521
Common stock, shares outstanding	182,336,310	19,455,896
Treasury stock, shares	1,025,625	690,625
Unamortized discount convertible notes payable, current	$ 375,518	$ 369,569
Unamortized discount convertible notes payable, non current	$ 19,159	$ 507,360
Series A Preferred stock
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares outstanding	500,000	500,000
Series B Preferred Stock
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	30,000,000	30,000,000
Preferred stock, shares outstanding

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)		3 Months Ended
		Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Revenue		$ 246,828	$ 386,643
Cost of revenue		205,409	149,886
Gross profit		41,419	236,757
Operating expenses:
Sales and marketing [A]	[1]	133,820	69,280
Research and development		35,599	51,853
General and administrative [B]	[2]	304,032	974,707
Total operating expenses		473,451	1,095,840
Operating loss		(432,032)	(859,083)
Other income (expense):
Interest expense		(710,552)	(77,990)
Interest expense - related party		(4,238)	(145,563)
Change in warrant liability		$ 20,902	1,409,825
Gain on settlement			257,930
Total other income (expense), net		$ (693,888)	1,444,202
Income (loss) before provision for income taxes		(1,125,920)	585,119
Provision for income taxes		800	2,209
Net income (loss)		$ (1,126,720)	$ 582,910
Net loss available to common shareholders:
Income (loss) per common share - basic		$ (0.01)	$ 0.06
Income (loss) per common share - diluted		$ (0.01)	$ 0.05
Weighted average shares - basic		84,039,785	10,692,552
Weighted average shares - diluted		84,039,785	12,803,063
[1]	Stock-based compensation was $32,343 and $0 for the three months ended December 31, 2015 and 2014, respectively.
[2]	Stock-based compensation was $34,800 and $612,549 for the three months ended December 31 2015 and 2014, respectively.

Consolidated Statements of Ope5

Consolidated Statements of Operations (Parenthetical) (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Stock-based compensation	$ 36,000	$ 612,549
Sales and marketing [Member]
Stock-based compensation	32,343	0
General and administrative [Member]
Stock-based compensation	$ 34,800	$ 612,549

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit (Unaudited) - 3 months ended Dec. 31, 2015 - USD ($)	Total	Common Stock to be Issued	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Prepaid Stock-based Compensation	Treasury Stock	Series A Preferred stock	Series B Preferred Stock
Balance at Sep. 30, 2015	$ (385,013)		$ 192	$ 26,660,868	$ (26,611,042)		$ (435,031)
Balance, Shares at Sep. 30, 2015			19,205,896					500,000
Conversion of notes payable and accrued interest	804,453		$ 1,366	803,087
Conversion of notes payable and accrued interest, Shares			136,633,909
Conversion of unpaid wages	93,334		$ 39	93,295
Conversion of unpaid wages, Shares			3,888,888
Common stock issued for services	31,689		$ 14	31,675
Common stock issued for services, Shares			1,442,617
Common stock issued for bonuses	36,000		$ 15	35,985
Common stock issued for bonuses, Shares			1,500,000
Discount on convertible note payable	$ 36,960			36,960
Surrender of common stock			$ (3)	$ 5,073			$ (5,070)
Surrender of common stock, Shares			(335,000)
Common stock to be issued	$ 90,000	$ 90,000
Common stock to be issued, Shares
Common stock issued to CEO			$ 200	$ 99,800		$ (100,000)
Common stock issued to CEO, Shares			20,000,000
Net income	$ (1,126,720)				$ (1,126,720)
Balance at Dec. 31, 2015	$ (419,297)	$ 90,000	$ 1,823	$ 27,766,744	$ (27,737,762)	$ (100,000)	$ (440,101)
Balance, Shares at Dec. 31, 2015			182,336,310					500,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net income (loss)	$ (1,126,720)	$ 582,910
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation	38,614	13,495
Accretion of debt discounts	697,285	204,017
Fair value in excess of stock issued for conversion of notes payable and accrued interest	$ 119	12,498
Fair value in excess of stock issued for conversion of related party notes payable and accrued interest		9,630
Gain on change in warrant liability	$ (20,902)	(1,409,825)
Gain on settlement		$ (257,930)
Common stock issued for services	$ 31,689
Stock-based compensation	36,000	$ 612,549
Changes in operating assets and liabilities:
Accounts receivable	(2,755)	(9,096)
Inventory	(178,150)	(77,734)
Other assets	(2,828)	(36,116)
Accounts payable	86,358	80,158
Accrued expenses	68,916	40,763
Net cash used in operating activities	(372,374)	(234,681)
Cash flows from investing activities:
Capital expenditures	$ (39,925)	(19,385)
Purchase of trademarks and pending patents		(5,025)
Net proceeds from settlement		62,930
Net cash provided by (used in) investing activities	$ (39,925)	$ 38,520
Cash flows from financing activities:
Net proceeds from common stock to be issued	90,000
Net proceeds from issuance of convertible notes payable	46,000	$ 475,000
Net proceeds from issuances of related party convertible notes payable	$ 50,000
Repayments on related party convertible notes payable		$ (52,828)
Net cash provided by financing activities	$ 186,000	422,172
Net change in cash	(226,299)	226,011
Cash, beginning of period	273,904	48,370
Cash, end of period	$ 47,605	274,381
Cash paid during the period for:
Interest		1,588
Taxes	$ 800	2,209
Non-cash investing and financing activities:
Conversion of notes payable and accrued interest	$ 804,453	220,262
Conversion of related party notes payable and accrued interest		341,747
Original issue discount recorded with convertible note payable		50,000
Beneficial conversion feature recorded with convertible notes payable	$ 36,960	$ 168,000

Description of Business and Sum

Description of Business and Summary of Significant Accounting Policies	3 Months Ended
	Dec. 31, 2015
Description of Business and Summary of Significant Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BUSINESS Vape Holdings, Inc. (“VAPE,” the “Company,” “we,” “us,” “our,” “our company”) is a holding company with its primary focus in the manufacturing and distribution of healthy and sustainable vaporization products. The Company designs, markets and distributes ceramic vaporization products under a unique brand. The Company has introduced a nonporous, non-corrosive, chemically inert medical-grade ceramic vaporization element as a healthy, sustainable alternative to traditional titanium and quartz vaporization materials, as well as lower-grade ceramic found in traditional electronic cigarettes and vaporizers. This material can be used for a wide range of applications, including stand-alone vaporization products and "E-cigs." Electronic cigarettes come in a variety of designs ranging from those that look vastly like traditional cigarettes, to larger vaporizer units which are capable of vaporizing liquid with varying viscosity. The process of vaporization is believed to eliminate the smoke, tar, ash, and other byproducts of traditional smoking by utilizing lower temperatures in a controlled electronic environment. HIVE CERAMICS HIVE Ceramics (“HIVE”) is the premier brand under the VAPE umbrella. HIVE manufactures and distributes a proprietarily blended ceramic vaporization element for torched, electronic and portable vaporizers with countless design and product crossover capabilities in existing and emerging markets. HIVE is dedicated to bringing the healthiest and cleanest vaporization experience possible to the market. The HIVE product line currently consists of over 15 distinct ceramic elements, including the 2 piece domeless, domeless direct inject, and HIVE’s signature domeless elements covering 10mm, 14mm and 18mm applications as well as regular elements, the HIVE Flower Cup, the HIVE Carb Cap, HIVE Stinger Dabber, the 14mm HIVE x Quave - Club Banger, the HIVE x Brothership Honey Bucket and the HIVE x D-Nail 16mm and 20mm attachments. The Company intends to rely on a combination of trademark, copyright, trade secret and patent laws in the United States as well as confidentiality procedures and contractual provisions to protect future proprietary technology and its brands, as they are developed. The Company has created or acquired and continues in the process of creating and/or acquiring proprietary vaporizers and e-cigarettes, and various trademarks, patents and copyrights for brands which are developed or in development. The Company is actively engaged in improving and expanding lines of branded products through business alliances and acquisitions, as well as developing its branded retail business expansion. VAPE and its business units are organized and directed to operate strictly in accordance with all applicable state and federal laws. REVIVAL PRODUCTS On December 28, 2015, the Company created a new wholly-owned subsidiary, Revival Products, LLC (“Revival”), which is in the business of portable vaporization devices. Revival will sell disposable cartridges that complement HIVE Ceramic’s product lines utilizing its sales and distribution channels and via its own designated e-commerce site at www.revivalvapes.com BETTERCHEM On July 1, 2015, the Company entered into a Share Exchange Agreement with BetterChem Consulting, Inc. (“BetterChem”), a Pennsylvania corporation, and its sole shareholder and the Company’s current Chief Science Officer Dr. Mark Scialdone (“Dr. Scialdone”), whereby the Company acquired a controlling 80% interest in BetterChem from Dr. Scialdone in exchange for up to 400,000 shares of the Company’s restricted common stock. In consideration for the issuance of the shares to Dr. Scialdone, the Company acquired 80 shares of the common stock of BetterChem which represents 80% of the issued and outstanding shares of BetterChem. Dr. Scialdone retained a 20% interest in BetterChem. The Share Exchange Agreement transaction closed concurrently with its execution on July 1, 2015 and was approved by Unanimous Written Consent of the Board of Directors (the “Board”) of the Company on the same date. At closing, the Company issued 250,000 shares of its common stock valued at $67,500 to BetterChem. BetterChem had no identifiable assets and liabilities upon closing, and no significant revenues. On January 12, 2016, the Company unwound the transaction and curtailed the subsidiary’s operations in order to reduce overhead costs and focus on HIVE Ceramics. An impairment of the acquisition of BetterChem will be recorded on January 12, 2016 totaling approximately $65,000. VAPE is organized and directed to operate strictly in accordance with all applicable state and federal laws. GOING CONCERN VAPE’s consolidated financial statements reflect a net loss of $1,126,720 during the three months ended December 31, 2015. As of December 31, 2015, we had cash of $47,605 and a working capital deficit of $331,421. VAPE has suffered an accumulated deficit of $27,737,762 and during the three months ended December 31, 2015, the Company took steps to curtail its Offset, HIVE Glass and HIVE Supply business lines to focus more on consumer vaporization products including the launch of “Revival” discussed above. The Company also curtailed its ‘THE HIVE’ retail store in order to reduce overhead costs and focus on HIVE Ceramics. Moreover, the Company curtailed its exploration into providing real estate, management and consulting solutions to the legal cannabis industry in states where such cannabis cultivation and extraction is legal. The Company was never able to execute on any of these plans and ultimately determined that the Company’s capital reserves for such projects as well as the risks inherent in each project due to the current regulatory environment surrounding the cannabis industry made this line of business too difficult to pursue. All of which have resulted in losses and opportunity costs. In addition, the ongoing need to obtain financing to fund operations also raise substantial doubt about the ability of Vape to continue as a going concern. Management expects to obtain funding for operations for the foreseeable future; however, there are no assurances that the Company will obtain such funding. VAPE’s financial statements do not include any adjustments to reflect the possible effects on recoverability and classification of assets or the amounts and classification of liabilities that may result from the inability to continue as a going concern. See Note 10 for subsequent events regarding financing activities.

Accounting Policies and Basis o

Accounting Policies and Basis of Presentation	3 Months Ended
	Dec. 31, 2015
Accounting Policies and Basis of Presentation [Abstract]
ACCOUNTING POLICIES AND BASIS OF PRESENTATION	NOTE 2. ACCOUNTING POLICIES AND BASIS OF PRESENTATION BASIS OF PRESENTATION The accompanying unaudited interim consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the SEC. Certain information and disclosures normally included in the annual financial statements prepared in accordance with the accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments and disclosures necessary for a fair presentation of these consolidated financial statements have been included. Such adjustments consist of normal recurring adjustments. The current results are not an indication of the full year. CONSOLIDATION The consolidated financial statements include the assets, liabilities, and operating results of the Company and its wholly-owned subsidiaries, Revival and Nouveau after elimination of all material inter-company accounts and transactions. USE OF ESTIMATES The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions include losses for warrant contingencies and the valuation of conversion features in notes. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Applicable accounting guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. There are three levels of inputs that may be used to measure fair value: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - Include other inputs that are directly or indirectly observable in the marketplace. Level 3 - Unobservable inputs which are supported by little or no market activity. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Derivative instruments include the warrant liability (Level 2). Derivative instruments are valued using standard calculations/models that are primarily based on observable inputs, including volatilities and interest rates. Therefore, derivative instruments are included in Level 2. Fair-value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2015 and September 30, 2015. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values. These financial instruments include cash, prepaid expenses, accounts payable, accrued liabilities, and notes payable. Fair values for these items were assumed to approximate carrying values because of their short-term nature or they are payable on demand. The following table presents the Company’s fair value hierarchy for assets measured at fair value on a recurring basis at December 31, 2015: Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents $ 47,605 $ - $ - $ 47,605 Total assets measured at fair value $ 47,605 $ - $ - $ 47,605 Liabilities Derivative instruments $ - $ 4,123 $ - $ 4,123 Total liabilities measured at fair value $ - $ 4,123 $ - $ 4,123 The following table presents the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis at September 30, 2015: Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents $ 273,904 $ - $ - $ 273,904 Total assets measured at fair value $ 273,904 $ - $ - $ 273,904 Liabilities Derivative instruments $ - $ 25,025 $ - $ 25,025 Total liabilities measured at fair value $ - $ 25,025 $ - $ 25,025 CONCENTRATION Credit Risk At times, the Company maintains cash balances at a financial institution in excess of the FDIC insurance limit. In addition, at we extend credit to customers in the normal course of business, after we evaluate the credit worthiness. The Company does not expect to take any unnecessary credit risks causing significant write-offs of potentially uncollectible accounts. Customers Two (2) customers accounted for 80% of our accounts receivable as of December 31, 2015. One (1) customer accounted for 37% of our accounts receivable as of September 30, 2015. The loss of these customers would have a significant impact on the Company’s financial results. Suppliers Two (2) suppliers accounted for 97% of our purchases during the three months ended December 31, 2015. One (1) supplier accounted for 100% of our purchases during the three months ended December 31, 2014. The loss of these suppliers would have a significant impact on the Company’s financial results. REVENUE RECOGNITION The Company recognizes revenues from product sales when (a) persuasive evidence that an agreement exists; (b) the products have been delivered; (c) the prices are fixed and determinable and not subject to refund or adjustment; and (d) collection of the amounts due is reasonably assured. Revenue is generally recorded when sales orders are shipped. INVENTORY Inventory is valued at the lower of cost or market, as determined primarily by the average cost inventory method, and are stated using the first-in, first-out (FIFO) method. Management will record a provision for loss for obsolete or slow moving inventory to reduce carrying amounts to net realizable value. We purchase product sourced from China which we are required to pay 50% upon placing the order. Amounts paid for products, which have not been received, are recorded as prepaid inventory. There are no amounts paid which are in dispute or considered impaired. FIXED ASSETS Fixed assets are recorded at cost and depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The estimated life of tooling related to our ceramic products is two (2) years. The estimated life of our leasehold improvements is the lesser of the term of the related lease and useful life of the asset. IMPAIRMENT OF LONG-LIVED AND PURCHASED INTANGIBLE ASSETS The Company has adopted Accounting Standards Codification (“ASC”) 350 “Intangibles - Goodwill and Other.” The Statement requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undercounted cash flows. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 350 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell. Long-lived assets, such as fixed assets and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the asset is measured by comparison of its carrying amount to undiscounted future net cash flows the asset is expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair market value. Estimates of expected future cash flows represent management's best estimate based on currently available information and reasonable and supportable assumptions. Any impairment recognized is permanent and may not be restored. During the three months ended December 31, 2015 and 2014, the Company did not record any impairment of its trademarks and pending patents as its expected future cash flows are in excess of their carrying amounts. RESEARCH AND DEVELOPMENT Research and development costs are expensed as incurred. The costs of materials and equipment that will be acquired or constructed for research and development activities, and that have alternative future uses, both in research and development, marketing or sales, will be classified as fixed assets and depreciated over their estimated useful lives. To date, research and development costs include the research and development expenses related to prototypes of the Company’s products. During the three months ended December 31, 2015 and 2014, research and development costs were $35,599 and $51,853, respectively. CONVERTIBLE DEBT Convertible debt is accounted for under the guidelines established by ASC 470-20 “Debt with Conversion and Other Options.” ASC 470-20 governs the calculation of an embedded beneficial conversion, which is treated as an additional discount to the instruments where derivative accounting (explained below) does not apply. The amount of the value of warrants and beneficial conversion feature may reduce the carrying value of the instrument to zero, but no further. The discounts relating to the initial recording of the derivatives or beneficial conversion features are accreted over the term of the debt. Many of the conversion features embedded in the Company's convertible notes are variable and are adjusted based on a discount to market prices which could cause an unlimited number of common stock to be issued. The management and board of directors currently have the ability to authorize additional shares of common stock primarily through their super voting rights under the Series A Preferred stock (See “NOTE 8 - STOCKHOLDERS’ DEFICIT”). When applicable, the Company calculates the fair value of warrants and conversion features issued with the convertible instruments using the Black-Scholes valuation method, using the same assumptions used for valuing employee options for purposes of ASC 718 “Compensation - Stock Compensation”, except that the contractual life of the warrant or conversion feature is used. Under these guidelines, the Company allocates the value of the proceeds received from a convertible debt transaction between the conversion feature and any other detachable instruments (such as warrants) on a relative fair value basis. The allocated fair value is recorded as a debt discount or premium and is amortized over the expected term of the convertible debt to interest expense. If the fair value exceeds the carrying value of the debt, an immediate charge to operations is recorded by management. Each reporting period, the Company will compute the estimated fair value of derivatives and record changes to operations. Currently no instruments are being recorded as such. The Company accounts for modifications of its BCF’s in accordance with ASC 470-50 “Modifications and Extinguishments.” ASC 470-50 requires the modification of a convertible debt instrument that changes the fair value of an embedded conversion feature and the subsequent recognition of interest expense or the associated debt instrument when the modification does not result in a debt extinguishment. DERIVATIVE FINANCIAL INSTRUMENTS Derivative financial instruments, as defined in ASC 815, “Accounting for Derivative Financial Instruments and Hedging Activities”, consist of financial instruments or other contracts that contain a notional amount and one or more underlying (e.g. interest rate, security price or other variable), require no initial net investment and permit net settlement. Derivative financial instruments may be free-standing or embedded in other financial instruments. Further, derivative financial instruments are initially, and subsequently, measured at fair value and recorded as liabilities or, in rare instances, assets. The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has issued financial instruments including senior convertible notes payable and freestanding stock purchase warrants with features that are either (i) not afforded equity classification, (ii) embody risks not clearly and closely related to host contracts, or (iii) may be net-cash settled by the counterparty. As required by ASC 815, in certain instances, these instruments are required to be carried as derivative liabilities, at fair value, in our consolidated financial statements. The Company estimates the fair values of derivative financial instruments using various techniques (and combinations thereof) that are considered to be consistent with objectively measuring fair values. In selecting the appropriate technique, consideration is given to, among other factors, the nature of the instrument, the market risks that it embodies and the expected means of settlement. For less complex derivative instruments, such as free-standing warrants, the Company generally uses the Black-Scholes option valuation technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fair value these instruments. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are highly volatile and sensitive to changes in the trading market price of our common stock, which has a high-historical volatility. Since derivative financial instruments are initially and subsequently carried at fair values, the Company's operating results will reflect the volatility in these estimate and assumption changes. EARNINGS (LOSS) PER COMMON SHARE Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing net income available to common shareholders by the combination of dilutive common share equivalents, comprised of shares issuable under the Company’s share-based compensation plans and the weighted-average number of common shares outstanding during the reporting period. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated, based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of an award, if any, the amount of compensation cost, if any, for future service that the Company has not yet recognized, and the estimated tax benefits that would be recorded in paid-in capital, if any, when an award is settled are assumed to be used to repurchase shares in the current period. In the event of losses, such common share equivalents are excluded as their effects are antidilutive. The following is a summary of outstanding securities that would have been included in the calculation of diluted shares outstanding since the exercise prices did not exceed the average market value of the Company’s common stock if the Company generated net income for the three months ended December, 2015: For the Three Months Ended December 31, 2015 Series A Preferred stock 500,000 Common stock options - Common stock warrants 1,184,727 Convertible notes 535,890,076 537,574,803 The following is a summary of outstanding securities which have been included in the calculation of diluted net income per share and reconciliation of net income to net income available to common stock holders for the three months ended December 31, 2014: For the Three Months Ended Weighted average common shares outstanding used in calculating basic earnings per share 10,692,552 Effect of Series A preferred stock 500,000 Effect of convertible notes payable 1,465,565 Effect of options and warrants 144,946 Weighted average common and common equivalent shares used in calculating diluted earnings per share 12,803,063 Net income as reported $ 582,910 Add - Interest on convertible notes payable 88,865 Net income available to common stockholders $ 671,775 The Company excluded 1,005,000 warrants from the computation for the three months ended December 31, 2014, as their exercise prices were in excess of the average closing market price of the Company’s common stock, causing their effects to be anti-dilutive using the treasury stock method. STOCK-BASED COMPENSATION ASC 718, “Share-Based Payment” requires that compensation cost related to share-based payment transactions be recognized in the consolidated financial statements. Share-based payment transactions within the scope of ASC 718 include stock options, restricted stock plans, performance-based awards, stock appreciation rights, and employee share purchase plans. The Company adopted ASC 718, which requires disclosure of the fair value and other characteristics of stock options and more prominent disclosure about the effects of an entity’s accounting policy decisions with respect to stock-based compensation on reported net loss. The Company has reflected the expense of such stock based compensation based on the fair value at the grant date for awards consistent with the provisions of ASC 718. In connection with the adoption of ASC 718, the fair value of our share-based compensation has been determined utilizing the Black-Scholes pricing model. The fair value of the options granted is amortized as compensation expense on a straight line basis over the requisite service period of the award, which is generally the vesting period. The fair value calculations involve significant judgments, assumptions, estimates and complexities that impact the amount of compensation expense to be recorded in current and future periods. Upon option exercise, the Company issues new shares of stock. The following weighted average variables were used in the Black Scholes model for all option issuances valued during the three months ended December 31, 2015 and 2014: Three Months Stock Price at Dividend Exercise Risk Free Volatility Average 2015 n/a n/a n/a n/a n/a n/a 2014 $ 0.73 n/a $ 0.73 2.2 % 380 % 10.0 The Company's accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of Emerging Issues Task Force (“EITF”) 96-18, “Accounting for Equity Instruments That are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services”, codified into ASC 505-50. The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor's performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement. Prepaid stock-based compensation is recorded when shares are issued based on the value on the grant date, but vest over the contractual period at which time the prorated expense will be recorded. RECENT ACCOUNTING PRONOUNCEMENTS In April 2015, the FASB issued Accounting Standard Update ("ASU") 2015-03 Simplifying the Presentation of Debt Issuance Costs. This update requires capitalized debt issuance costs to be classified as a reduction to the carrying value of debt rather than a deferred charge, as is currently required. This update will be effective for the Company for all annual and interim periods beginning after December 15, 2015 and is required to be adopted retroactively for all periods presented, and early adoption is permitted. The Company will adopt the policy during the quarter ending March 31, 2016. In May 2014, the FASB issued Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers”, which supersedes most of the current revenue recognition requirements. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for these goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. This guidance is effective for the Company in the first quarter of fiscal year 2018 and early application is not permitted. Entities must adopt the new guidance using one of two retrospective application methods. The Company is currently evaluating the standard but does not expect it to have a material impact on our financial position, results of operations or cash flows. In August 2014, the FASB issued ASU 2014-15, which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued.2 An entity must provide certain disclosures if “conditions or events raise substantial doubt about the entity’s ability to continue as a going concern.” The ASU applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Financial Accounting Standards Board issues Accounting Standard Updates (“ASUs”) to amend the authoritative literature in Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of ASC. The Company believes those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on the Company. RISKS AND UNCERTAINTIES Although forward-looking statements in this Quarterly Report reflect our good faith judgment, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include without limitation those discussed under the heading “Risk Factors” below, as well as those discussed elsewhere in this Quarterly Report. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Quarterly Report. Readers are urged to carefully review and consider the various disclosures made in this Quarterly Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

Fixed Assets

Fixed Assets	3 Months Ended
	Dec. 31, 2015
Fixed Assets [Abstract]
FIXED ASSETS	NOTE 3. FIXED ASSETS The following is a summary of fixed assets as of December 31, 2015 and September 30, 2015: December 31, September 30, Molds and Tooling $ 215,940 $ 176,015 Leasehold improvements - 29,795 Accumulated depreciation (96,302 ) (87,483 ) $ 119,638 $ 118,327 During the three months ended December 31, 2015 and 2014, depreciation expense included in cost of revenue were $38,614 and $13,495, respectively.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Dec. 31, 2015
Accrued Expenses [Abstract]
ACCRUED EXPENSES	NOTE 4. ACCRUED EXPENSES The following is a summary of accrued expenses as of December 31, 2015 and September 30, 2015: December 31, September 30, Accrued interest $ 82,143 $ 46,337 Accrued interest - related party 28,776 24,538 Accrued wages and taxes 79,462 112,322 Other 17,800 25,468 $ 208,181 $ 208,665 As of December 31, 2015, $25,000 for Kyle Tracey, $16,667 for Joe Andreae, $10,000 for Mike Cook, $5,000 for Allan Viernes, and $5,000 for Benjamin Beaulieu are recorded in accrued wages.

Third Party Debt

Third Party Debt	3 Months Ended
	Dec. 31, 2015
Third Party Debt [Abstract]
THIRD PARTY DEBT	NOTE 5. THIRD PARTY DEBT CONVERTIBLE NOTES PAYABLE Beginning on February 11, 2014, the Company issued 6% Convertible Notes (the “6% Notes”) pursuant to subscription agreements to ten (10) accredited investors (the “Holders”) with the aggregate principal amount of $230,000. The 6% Notes are not secured by any collateral or any assets pledged to the Holders. The maturity dates are from February 28, 2015 to March 31, 2015, and the annual rate of interest is six percent (6%). Subject to certain limitations, the Holders can, at their sole discretion, convert the outstanding and unpaid principal and interest of their notes into fully paid and nonassessable shares of the Company’s common stock. The conversion price of these 6% Notes is the average of the fifteen (15) lowest daily VWAP’s occurring during the twenty (20) consecutive trading days immediately preceding the date each Holder elects convert all of their 6% Note minus a discount of 40%. In no event will the conversion price be less than $1.00 per share or greater than $3.00 per share. The Company had a preexisting relationship with each of the Holders, and no general solicitation or advertising was used in connection with the issuance of the 6% Notes. We recorded a discount totaling $92,000 related to the beneficial conversion feature embedded in the notes upon issuance and amortized $32,333 and $57,667 of the discount to interest expense during the year ended September 30, 2015 and 2014, respectively. On March 12, 2015, the Company offered to pay accrued interest and modify the terms of the six (6) Holders’ outstanding 6% Notes, decreasing the conversion floor from $1.00 to $0.50 in order to encourage the noteholders to convert their promissory notes. The Company recorded a loss on debt extinguishment of $23,443 as a result of the fair value in excess of the modified conversion floor. In March 2015, the Company paid all accrued interest on the 6% notes of $17,200. Five (5) of the six (6) holders converted in full a total of $80,000 of 6% Notes into 160,000 shares of common stock. The remaining note holder partially converted $20,000 of 6% Notes into 40,000 of common shares and extended the terms on the remaining $30,000 for six (6) months. In December 2015, the Company further modified the terms for the last remaining holder of the 6% Notes, removing the conversion floor and conversion terms in order to encourage the holder to convert. On December 14, 2015, the note holder converted $30,000 in principal and $1,351 of accrued interest into 13,063,013 shares of common stock. As of December 31, 2015, none of the 6% Notes remain outstanding. Securities Purchase Agreement On December 3, 2014, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with an accredited investor (the “Investor”) pursuant to which the Company agreed to sell, and the Investor agreed to purchase, an unsecured convertible promissory note (the “Note”) in the principal amount of $560,000 less an original issue discount (“OID”) of $50,000 and transaction expenses of $10,000 for a total purchase price of $500,000. The Company also paid a finder’s fee in the amount of $25,000 in connection with this transaction, which was recorded as a discount to the note as it was paid from the proceeds. The closing under the Securities Purchase Agreement occurred on December 3, 2014. The Company received $475,000 net proceeds after transactions costs. We amortized $12,162 and $2,778 of the discount to interest expense during the three months ended December 31, 2015 and 2014, respectively. In addition, the Company recorded $45,940 in deferred financing costs and amortized $7,657 and $2,552 to interest expense during the three months ended December 31, 2015 and 2014, respectively. As of December 31, 2015, the Company had unamortized costs of $12,761 in current deferred financing costs. The deferred financing costs are amortized through the maturity date. The Note bears interest at the rate of 10% per annum and is convertible into common stock of the Company at a conversion price per share of 70% of the average of the three (3) lowest Closing Sale Prices in the ten (10) Trading Days immediately preceding the applicable Conversion (subject to adjustment in the event of stock splits, stock dividends, and similar transactions, and in the event of subsequent sales of common stock at a lower purchase price (subject to certain exceptions))(the “Conversion Price”). In no event will the Conversion Price be less than $0.50 per share. Repayment of principal on the Note, together with accrued interest thereon, is due in twelve monthly installments, commencing six months from issuance. The Company may make such payments in cash (in which event the Company will pay a 25% premium) or, subject to certain conditions, in shares of common stock valued at the lower of the Conversion Price or 70% of the average of the three (3) lowest Closing Sale Prices in the ten (10) Trading Days immediately preceding the applicable payment date (the “Amortization Conversion Rate”). The Maturity Date of the Note is seventeen months from the date of issuance. We recorded a discount totaling $168,000 related to the beneficial conversion feature embedded in the note upon issuance. On August 26, 2015, the Company and Investor entered into an Amendment whereby the conversion rate of the note was amended to 55% of the lowest price of the prior fifteen (15) trading days and conversion floor removed which amendment was triggered by the dilutive issuances of the August 2015 convertible note financing thereby entitling Investor to the lowest conversion rate granted during the year ended September 30, 2015 per the terms of the Securities Purchase Agreement. As a result, we expensed the unamortized discount of $168,000 to interest expense, recorded a loss on debt extinguishment of $158,916, and recorded a new discount of $242,916. We amortized $116,332 of the discount to interest expense during the three months ended December 31, 2015. On December 10, 2015, the Company and the Investor entered into a forbearance agreement regarding the Investor’s convertible note and added $105,000 to the principal. Between October 2015 and December 2015, the Company issued the following conversions for payment towards Investor: Conversion Date Principal Accrued Total Conversion Common October 8, 2015 $ 21,000 $ - $ 21,000 $ 0.012 1,818,182 October 16, 2015 18,900 - 18,900 $ 0.012 1,636,364 October 22, 2015 25,800 - 25,800 $ 0.011 2,333,786 October 29, 2015 22,460 - 22,460 $ 0.011 2,031,660 November 11, 2015 33,500 - 33,500 $ 0.007 4,649,549 November 18, 2015 24,000 - 24,000 $ 0.006 4,195,804 November 30, 2015 30,000 - 30,000 $ 0.005 5,741,627 December 11, 2015 22,000 - 22,000 $ 0.002 9,090,909 December 28, 2015 22,500 - 22,500 $ 0.002 9,297,521 $ 220,160 $ - $ 220,160 40,795,402 Subsequent to year end, the Investor also enacted the following conversions: Conversion Date Principal Converted Accrued Interest Converted Total Converted Conversion Rate Common Shares Issued January 7, 2016 20,000 - 20,000 $ 0.002 10,101,010 January 20, 2016 12,500 - 12,500 $ 0.001 10,330,579 February 2, 2016 13,200 13,200 $ 0.001 10,909,091 $ 45,700 $ - $ 45,700 31,340,680 As a result, as of December 31, 2015, $120,684 and $26,541, net of total unamortized discounts of $87,121 and $19,159 are classified as current and long-term on the accompanying consolidated balance sheet. As of September 31, 2015, there is $18,541 in accrued interest expense related to this note and the Company recorded $8,596 in interest expense related to this note during the three months ended December 31, 2015. $2M Securities Purchase Agreement On February 10, 2015, the Company entered into a securities purchase agreement (the “February 2015 Securities Purchase Agreement”) with an accredited investor pursuant to which the Company agreed to sell, and the investor agreed to purchase, an unsecured convertible promissory note (the “$2M Note”) in the principal amount of $2,000,000 less an OID of $182,000 and transaction expenses of $10,000 for a total purchase price of $1,808,000. The closing under the February 2015 Securities Purchase Agreement occurred on February 10, 2015. The $2M Note bears interest at the rate of 10% per annum and is immediately convertible into common stock of the Company at a conversion price per share of 70% of the lowest daily VWAP in the ten (10) Trading Days immediately preceding the applicable Conversion (subject to adjustment in the event of stock splits, stock dividends, and similar transactions, and in the event of subsequent sales of common stock at a lower purchase price (subject to certain exceptions))(the “Conversion Price”). In no event will the Conversion Price be less than $0.50 per share. Repayment of principal on the $2M Note, together with accrued interest thereon, is due in twelve bi-monthly installments, commencing approximately six months from issuance. The Company may make such payments in cash (in which event the Company will pay a 25% premium) or, subject to certain conditions, in shares of common stock valued at the lower of the Conversion Price or 70% of the lowest daily VWAP in the ten (10) Trading Days immediately preceding the applicable payment date (the “Amortization Conversion Rate”). The Maturity Date of the $2M Note is twelve months from the date of issuance. During the year ended September 30, 2015, the Company received $800,000 toward the $2M Note with an original issue discount of $148,600 and transaction costs for net proceeds of $651,395, respectively. We amortized $45,600 of the discount to interest expense during the year ended September 30, 2015. In addition, we recorded a discount totaling $108,641 related to the beneficial conversion feature embedded in the note upon issuance. On August 13, 2015, the Company entered into an Amendment, Waiver and Modification Agreement (the “Amendment”) to its $2M Securities Purchase Agreement and related Transaction Documents with Redwood Management, LLC including any designees and or assignees thereto. Under the terms of the Amendment, the parties agreed to reduce the $2,000,000 outstanding balance of the $2M Note to $800,000 to reflect the total amount funded under the note, to terminate the offsetting investor note securing the additional unfunded balance and to waive any past claims of default or offsetting interest on the $2M Note or investor note. In addition, the conversion rate of the note was amended to 55% of the lowest price of the prior fifteen (15) trading days and conversion floor removed which amendment was triggered by the dilutive issuances of the August 2015 convertible note financing thereby entitling Investor to the lowest conversion rate granted during the year ended September 30, 2015 per the terms of the $2M Securities Purchase Agreement. As a result, we expensed the unamortized discount of $108,641 to interest expense, recorded a loss on debt extinguishment of $385,815, and recorded a new discount of $440,000. We amortized $94,131 of the discount to interest expense during the year ended September 30, 2015. The following is summary of conversions by the $2M Note holder (including its assignees) during the three months ended December 31, 2015: Conversion Date Principal Converted Accrued Interest Converted Total Converted Conversion Rate Common Shares Issued October 1, 2015 $ 10,000 $ - $ 10,000 $ 0.0148 675,676 October 5, 2015 10,000 - 10,000 $ 0.0148 675,676 October 6, 2015 13,262 - 13,262 $ 0.0138 961,000 October 7, 2015 10,000 - 10,000 $ 0.0115 865,801 October 9, 2015 11,728 - 11,728 $ 0.0116 1,011,000 October 9, 2015 10,000 - 10,000 $ 0.0115 865,801 October 12, 2015 14,680 - 14,680 $ 0.0115 1,271,000 October 13, 2015 11,601 - 11,601 $ 0.0116 1,000,052 October 15, 2015 14,680 - 14,680 $ 0.0115 1,271,000 October 19, 2015 17,400 - 17,400 $ 0.0116 1,500,000 October 19, 2015 15,000 - 15,000 $ 0.0116 1,298,701 October 20, 2015 16,650 - 16,650 $ 0.0111 1,500,000 October 21, 2015 17,500 - 17,500 $ 0.0115 1,515,152 October 23, 2015 20,000 - 20,000 $ 0.0115 1,731,602 October 26, 2015 24,420 - 24,420 $ 0.0111 2,200,000 October 29, 2015 26,640 - 26,640 $ 0.0111 2,400,000 November 2, 2015 29,970 - 29,970 $ 0.0111 2,700,000 November 2, 2015 20,000 - 20,000 $ 0.0111 1,809,136 November 5, 2015 32,190 - 32,190 $ 0.0111 2,900,000 November 10, 2015 28,800 - 28,800 $ 0.0096 3,000,000 November 12, 2015 23,930 - 23,930 $ 0.0072 3,323,611 November 17, 2015 16,500 - 16,500 $ 0.0060 2,727,273 November 19, 2015 1,640 11,225 12,865 $ 0.0056 2,316,013 November 23, 2015 23,111 - 23,111 $ 0.0056 4,127,000 November 27, 2015 24,750 - 24,750 $ 0.0055 4,500,000 December 2, 2015 18,450 - 18,450 $ 0.0041 4,500,000 December 8, 2015 18,000 - 18,000 $ 0.0036 5,000,000 December 11, 2015 13,368 - 13,368 $ 0.0024 5,570,000 December 16, 2015 14,181 - 14,181 $ 0.0024 5,860,000 December 22, 2015 15,488 - 15,488 $ 0.0024 6,400,000 December 29, 2015 17,666 17,666 $ 0.0024 7,300,000 $ 541,604 $ 11,225 $ 552,830 82,775,494 As a result, as of December 31, 2015, $25,445, net of total unamortized discounts of $29,541 are classified as current on the accompanying consolidated balance sheet. During the three months ended December 31, 2015, the Company amortized $28,121 of the original issue discount to interest expense during the three months ended December 31, 2015 of which an unamortized discount of $3,079 remains as of December 31, 2015. In addition, we recorded a discount totaling $108,641 related to the beneficial conversion feature embedded in the note upon issuance. As of December 31, 2015, there is $42,867 in accrued interest expense related to this note, respectively, and the Company recorded $4,781 in interest expense related to this note during the three months ended December 31, 2015. Convertible Note Financing On August 5, 2015, the Company entered into a series of convertible note financings with several accredited investors totaling an aggregate of $541,000 in aggregate proceeds raised less certain fees and costs as set forth in the financing documents known as the “August 2015 Notes”. The financing was disclosed on the Company’s Current Report on Form 8-K filed on August 11, 2015 and is incorporated herein by reference. The Company recorded an original issue discount of $12,500 along with these notes and amortized $1,563 of the discount to interest expense during the three months ended December 31, 2015. The Company also recorded a beneficial conversion feature of $253,617 towards the notes and amortized $73,025 of the discount to interest expense during the three months ended December 31, 2015. As of December 31, 2015, there is $17,444 of accrued interest related to these notes and the Company recorded $9,057 in interest expense related to the notes during the three months ended December 31, 2015. On August 12, 2015, the Company entered into an additional convertible note financing transaction with an accredited investor in the principal amount of $105,000 less fees and costs. The closing under the financing occurred concurrently with the execution of the financing documents on August 12, 2015. The convertible note bears interest at the rate of 8% per annum and is convertible into common stock of the Company at any time after 180 days from issuance of the note at a conversion price per share equal to 58% of the average of the lowest trading price of the common stock in the thirteen (13) trading days immediately preceding the applicable conversion date. The Company has the option to prepay the convertible note in the first 180 days from closing subject to a prepayment penalty of 150% of principal plus interest. The maturity date of the convertible note is June 12, 2016 subject to the noteholder’s right to extend maturity an additional nine (9) month period. The Company recorded an original issue discount of $5,000 along with these notes and amortized $1,500 of the discount to interest expense during the three months ended December 31, 2015. The Company also recorded a beneficial conversion feature of $60,900 towards the notes and amortized $18,270 of the discount to interest expense during the three months ended December 31, 2015. As of December 31, 2015, there is $3,290 of accrued interest related to this note and the Company recorded $2,147 in interest expense related to the notes during the three months ended December 31, 2015. The foregoing descriptions of the August 12, 2015 note financing and related documentation do not purport to be complete and are qualified in their entirety by reference to the full text of the documents, which are filed as exhibits to this Quarterly Report on Form 10-K and are incorporated herein by reference. See Note 10 regarding subsequent events for an update on status of the August 2015 Convertible Note Financing. As of December 31, 2015 all notes, issuance costs, and discounts, except amounts subsequently converted are recorded as current due to the issues described in Note 10 related to note conversions. Additional Funding Under August 2015 Note On December 15, 2015, an accredited investor provided the Company with $50,000 in additional proceeds under the same terms of their original convertible note with a term of two years. A one-time interest charge of $11,600 was added to the principal of the note. The Company also recorded a beneficial conversion feature of $36,960 towards the note and amortized $1,540 of the discount to interest expense during the three months ended December 31, 2015. As of December 31, 2015, an unamortized discount of $35,420 remains and is expected to be amortized over the life of the note. The Company also recorded $4,000 of issuance costs as deferred financing costs and amortized $167 of the costs to interest expense during the three months ended December 31, 2015. As of December 31, 2015, deferred financing costs of $3,833 remain and is expected to be amortized over the life of the note. However, as a result of the issues described in Note 10 related to note conversions, the note, issuance costs, and accompanying discount have been recorded as current liabilities.

Related Party Debt

Related Party Debt	3 Months Ended
	Dec. 31, 2015
Related Party Debt [Abstract]
RELATED PARTY DEBT	NOTE 6. RELATED PARTY DEBT Related Party Note The Company had outstanding accounts payable balance to a related party (shareholder of the Company) in the amount of $15,000 as of September 30, 2013. This payable was converted into a note payable on December 7, 2013. The note payable bears interest of 6% per annum with a maturity date of December 1, 2016. As of December 31, 2015, there is $1,875 in accrued interest expense related to this note and the Company recorded $230 in interest expense related to this note during the three months ended December 31, 2015. Related Party Convertible Notes Payable On December 10, 2015, the Company entered into two Secured Series B Preferred Stock Convertible Notes (the “Series B Notes”) for an aggregate principal of $300,000 including 1) $50,000 from Hive Ceramics, LLC in new capital to the Company and 2) an amended and restated note for Hive Ceramics LLC in the amount of $250,000 for capital previously contributed which is soon to be due and payable. The Series B Notes accrue interest at eight percent (8%) per annum, mature one (1) year from issuance and are secured by all of the assets and property of the Company. Upon the election of the noteholder, the Series B Notes are convertible into newly created Series B Preferred Stock on a one-for-one (1:1) basis into shares of common stock of the Company at a fixed price per share of $0.01. Concurrently, the Company filed a Certificate of Designation with the Delaware Secretary of State on the Series B Preferred Stock which provides, in pertinent part, for the following rights and privileges: Authorized Amount of Series B Preferred Stock Voting Rights Rank pari passu As of December 31, 2015, $300,000 of the Series B Notes along with $26,902 of accrued interest are outstanding. The Board of Directors authorized the designation of the Series B Preferred Stock pursuant to the authority of the Certificate of Incorporation, which confers said authority on the Board, and the issuance of the Series B Notes pursuant to a unanimous written consent of the Board dated December 10, 2015. The value ascribed to the Series B Notes were based on the fixed conversion price of the instruments into common stock and such no beneficial conversion feature was recorded.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Dec. 31, 2015
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 7. COMMITMENTS AND CONTINGENCIES Office Lease As of December 31, 2015, the Company leases a 2,500 square foot office in Agoura Hills, California for approximately $2,500 per month which expires in December 2017. Warrant Liability The Company recorded the estimated settlement liability as of March 31, 2014 for the Warrant Shares issued and the Warrants that remain outstanding and unexercised that would be entitled to the same settlement based on the number of shares expected to be issued and the market price of the Company’s common stock on the dates of the actual settlements from $4.72 per share to $7.25 per share, and market price of the first settlement of $7.25 for the unsettled claims. We believe the issuance of convertible notes in the three months ended March 31, 2014 triggered the full ratchet anti-dilution adjustment; before the provision was triggered, the fair value of the warrant liability was not significant as the exercise was so far out of the money. As a result of the above settlements with warrant holders, the Company recorded a loss on settlement of warrants of $29,528,844 during the six months ended March 31, 2014 and a long-term warrant liability of $29,430,022 as of March 31, 2014 based on 4,407,200 shares of common stock under the settlement at the Company’s closing stock prices discussed above. As of December 31, 2015, the estimated settlement liability is $4,123 based on the fair market value of 1,184,727 remaining warrants and therefore the Company recorded a gain on the change in warrant liability of $20,902 and $1,409,825 during the three months ended December 31, 2015 and 2014, respectively. Settlement of Company Legal Claims On December 15, 2014, the Company recorded a gain on settlement of $257,930 for a confidential settlement by and between the Company and certain shareholders and related parties as settlement for certain potential legal claims held by the Company. As a result of the settlement, the Company received net proceeds of $62,930 and vendor credits of $200,000 during the three months ended December 31, 2014. A total of $325,000 in vendor credits has been received in connection with the settlement and no further credits will be given. In January 2015, the Company received 440,625 shares from the settlement that was assigned to officers of the Company. The officers decided it was in the best interest of the Company to return these shares to the Company to be used for future strategic issuances. Accordingly, the 440,625 shares valued at $367,531 were recorded as treasury stock as of December 31, 2015, and the Company recorded a gain on settlement of $0 and $257,930 during the three months ended December 31, 2015 and 2014, respectively. Resignations of Kyle Tracey and Joe Andreae; Appointment of Benjamin Beaulieu as Chairman On December 10, 2015, the Board accepted the resignation of Kyle Tracey as Chief Executive Officer, Chairman of the Board and all other officer positions held by him with the Company. Mr. Tracey will remain in a consultant role with the Company focusing on sales and business development of HIVE Ceramics for a period of two (2) years. Mr. Tracey also retains a large block of voting control of the Company due to the above issuance of the Series B Notes issued to HIVE Ceramics, LLC an entity he co-owns. The Board also accepted the resignation of Joe Andreae as President and a director as of December 10, 2015. The President seat will remain vacant until a qualified candidate is located. Benjamin Beaulieu was elevated from his position as a member of the Board to Chairman of the Board on December 10, 2015 to replace Mr. Tracey. Mr. Beaulieu also currently serves as the Company’s COO and will remain in that role. Appointment of Justin Braune as Chief Executive Officer On December 10, 2015, the Board appointed Justin Braune to serve as the Company’s Chief Executive Officer and as a director, effective immediately. Prior to joining the Company, Mr. Braune, 33, served as the chief operating officer of Voodoo Science, LLC and Vapor Wild from 2014 to 2015. From 2013 to 2014, Mr. Braune served as the Chief of Operations for Veracity Security, a technology company located in San Diego. From 2013-2014 Mr. Braune was the Director of Sales at Lear Capital. Since 2010 he owned and operated Braune Enterprises a real estate and investment brokerage firm. Mr. Braune graduated from the United States Naval Academy with a B.S. degree in electrical engineering in and was commissioned as an officer in the U.S. Navy. After earning his master’s degree in nuclear engineering, Mr. Braune operated the nuclear reactors onboard the USS RONALD REAGAN aircraft carrier. He served in the U.S. Navy until 2009 and subsequently earned his MBA at the University of Southern California, Marshall School of Business. Our Board believes that Mr. Braune’s extensive relationships and experience in the industry of vaporization products and e-cigarettes will bring added value to the Company’s management team. In connection with his appointment as Chief Executive Officer and a member of our Board, Mr. Braune entered into an employment agreement dated as of December 10, 2015 (the “Employment Agreement”) with the Company pursuant to which he will receive an annual salary of $150,000, subject to adjustment, and bi-monthly sales-based compensation of $1.00 USD per unit of wholesale sales of Mr. Braune’s new vaporizer pen product line and $3.00 USD per unit on retail sales. The sales-based compensation and salary is payable in cash or stock as further described in the Employment Agreement. In addition, the Company will issue to Mr. Braune 20,000,000 shares of the Company’s common stock, to be held in escrow and released by the Company to Mr. Braune in accordance with the following vesting schedule: (i) 5,000,000 shares shall vest on June 10, 2015, (ii) 5,000,000 shares shall vest on December 10, 2016, (iii) 5,000,000 shares shall vest on June 10, 2016, and (iv) 5,000,000 shares shall vest on December 10, 2016. Mr. Braune also is eligible to participate in any stock option plan maintained by the Company and available to other employees and standard benefit programs for similarly situated employees. The Employment Agreement continues until terminated by either party upon 30 days’ prior written notice. The grant date fair value was $100,000, which will be charged to operations evenly over the vesting period. The shares are considered issued and outstanding. Chief Science Officer On May 1, 2015, the Company appointed Dr. Mark A. Scialdone to the newly-created executive officer position of Chief Science Officer (“CSO”). Dr. Scialdone’s Executive Employment Agreement was for a period of two (2) years. Dr. Scialdone shall receive an annual salary of $102,000 and could have been eligible for any benefits made generally available by the Company. In connection with the unwind of BetterChem, Dr. Scialdone resigned from his position as CSO and waived all terms of severance under his agreement in exchange for remaining on the Company’s health insurance policy for six (6) months.

Stockholders' Deficit

Stockholders' Deficit	3 Months Ended
	Dec. 31, 2015
Stockholders' Deficit [Abstract]
STOCKHOLDERS' DEFICIT	NOTE 8. STOCKHOLDERS’ DEFICIT COMMON STOCK On November 27, 2013, the Board and shareholders approved an increase in the authorized number of shares of common and preferred stock which may be issued by the Company to 1,000,000,000 shares and 100,000,000 shares, respectively. On December 3, 2013, the certificate of amendment was filed with the Secretary of State of Delaware to reflect the increase in authorized. PREFERRED STOCK On April 1, 2014, the Board formally approved the filing of a Preferred Stock Designation in connection with the commitment of 500,000 Series A Shares to HIVE on March 27, 2014 pursuant to its authority to issue blank check preferred stock as provided in the Company’s Certificate of Incorporation. Per the Certificate of Designation (the “Designation”), there are 100,000,000 shares of preferred stock authorized by the Company’s Certificate of Incorporation. The Company is authorized to issue 500,000 shares of Series A Shares pursuant to the Designation. As provided in the Designation (and as set forth in the HIVE Asset Purchase Agreement), Series A Shares are entitled to vote at a 15-1 ratio to Common Stock. Each share of preferred stock shall initially be convertible into one share of common stock (500,000 shares of common stock in the aggregate). On the two year anniversary of the transaction of HIVE, the preferred stock conversion ratio shall be adjusted as follows: a one-time pro rata adjustment of up to ten-for-one (10-1) based upon the Company generating aggregate gross revenues over the two years of at least $8,000,000 (e.g. If the Company generates only $4,000,000 in aggregate gross revenues over the two year period then the convertible ratio will adjust to 5-1). In no event will the issuance convert into more than 5,000,000 shares of common stock of the Company. On June 19, 2014, the Company formally issued the 500,000 Series A Shares to HIVE. The value ascribed to the Series A Shares was based on the historical costs of the assets acquired on March 27, 2014 from HIVE since the transfer of assets was made among entities under common control. On December 10, 2015, the Company approved the filing of a Preferred Stock Designation for up to 30,000,000 shares of Series B Preferred Stock. No Series B Preferred Stock are issued or outstanding. See discussion of designation of Series B Preferred Stock in Note 6. COMMON STOCK ISSUED FOR ACCRUED WAGES On October 22, 2015, the Company’s Board of Directors issued 2,083,333 shares of restricted common stock each to Kyle Tracey at $0.024 per share for payment of $50,000 in accrued wages. On October 22, 2015, the Company’s Board of Directors issued 555,555 shares of restricted common stock each to Kyle Tracey at $0.024 per share for payment of $13,333 in accrued wages. On October 22, 2015, the Company’s Board of Directors issued 1,250,000 shares of restricted common stock each to Michael Cook at $0.024 per share for payment of $3,000 in accrued wages. COMMON STOCK ISSUED FOR BONUSES On October 22, 2015, the Company’s Board of Directors issued bonus stock grants of 600,000 shares of restricted common stock each to Allan Viernes and Benjamin Beaulieu at $0.024 per share. In addition, the Company issued 300,000 shares of restricted common stock to employees at $0.024 per share. These issuances were based on the fair market value on the date of issuance immediately vested and resulted in $36,000 being charged to general and administrative expense during the three months ended December 31, 2015. On October 22, 2015, the Company’s Board of Directors issued bonus stock grants of 1,250,000 shares of restricted common stock an outside sales consultant at $0.024 per share. The issuance was based on the fair market value on the date of issuance immediately vested and resulted in $30,000 being charged to sales and marketing expense during the three months ended December 31, 2015. COMMON STOCK ISSUED FOR SERVICES On November 25, 2015, the Company’s Board of Directors issued stock grants of 49,760 shares of restricted common stock a business development consultant at $0.011 per share. These issuances were based on the fair market value on the date of issuance immediately vested and resulted in $547 being charged to general and administrative expense during the three months ended December 31, 2015. On December 23, 2015, the Company’s Board of Directors issued stock grants of 142,857 shares of restricted common stock a business development consultant at $0.008 per share. These issuances were based on the fair market value on the date of issuance immediately vested and resulted in $1,143 being charged to general and administrative expense during the three months ended December 31, 2015. COMMON STOCK SURRENDERS On October 22, 2015, Joe Andreae surrendered 130,000 shares of restricted common stock valued at $3,120 and were recorded as treasury stock. In addition, on October 22, 2015, an employee also surrendered 30,000 shares valued at $360, which was recorded as treasury stock. On December 20, 2015, Kyle Tracey surrendered 130,000 shares of restricted common stock valued at $1,170 and were recorded as treasury stock. On December 21, 2015, the Allan Viernes and Benjamin Beaulieu each surrendered 30,000 shares of restricted common stock valued at $420, which was recorded as treasury stock. EQUITY INVESTMENT BY THE INVESTOR On December 10, 2015, the Investor purchased $90,000 in common stock at a purchase price equal to 90% of the average of the closing prices of the common stock for the three (3) trading days immediately preceding the date that is 6 months from the date of the agreement. As of December 31, 2015, proceeds of $90,000 have been recorded as common stock to be issued. WARRANTS The table below summarizes the Company’s warrant activity during the three month period ended December 31, 2015: Shares Weighted Average Weighted Average Remaining Contractual Term Aggregate Intrinsic Warrants outstanding at September 30, 2015 1,184,726 $ 0.114 0.9 $ 739,812 Warrants issued - - Warrants exercised - - Cancelled/forfeited/expired - - Warrants outstanding at December 31, 2015 1,184,726 $ 0.003 0.4 $ 18,387 The Company’s warrants above are accounted for as derivative liabilities in the accompanying consolidated balance sheets.

Intellectual Property

Intellectual Property	3 Months Ended
	Dec. 31, 2015
Intellectual Property [Abstract]
INTELLECTUAL PROPERTY	NOTE 9. INTELLECTUAL PROPERTY The Company plans to rely on a combination of trademark, copyright, trade secret and patent laws in the United States as well as confidentiality procedures and contractual provisions to protect future proprietary technology and its brands, as they are developed. The Company has begun to execute on this plan with the acquisition of the patent pending HIVE Ceramic vaporization product and the HIVE trademark as well as several pending trademark applications. The Company intends to continue to create or acquire proprietary vaporizers and e-cigarettes, and various trademarks, patents and/or copyrights for brands which are developed. TRADEMARKS On March 27, 2014, the Company and Stone Arch Studio, LLC entered into a Trademark Assignment Agreement whereby the Company acquired all right, title, priority and interest to the HIVE trademark U.S. Registration No. 44513069 as registered with the U.S. Patent and Trade Office (“USPTO”). This acquisition further protects the Company’s HIVE Ceramics brand vaporization line. In addition, the Company has filed for trademark protection with the USPTO on several additional trademarks and tradenames to be utilized by the Company in the future as the marks register. As of December 31, 2015, the Company has capitalized $123,150 in costs related to the trademarks. PATENTS On March 27, 2014, the Company formally closed its acquisition of the patent pending HIVE Ceramics vaporization technology. The Company has already begun exploiting this technology and intends to prosecute the patent application to completion. As of December 31, 2015, the Company has no patent costs capitalized. The Company is engaged in developing proprietary rights of the type that may be awarded patents for enhancements to its core HIVE product line as well as proprietary rights in related product lines. The Company also expects that from time to time it is in discussions to acquire additional patented technology from third parties to further grow and develop branded product lines in the vaporization market. See Note 1 regarding BetterChem unwind and rights to related patents.

Subsequent Events

Subsequent Events	3 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10. SUBSEQUENT EVENTS Third Party Debt Conversions See Note 5 for subsequent conversions related to third party debt. Common Stock Issued for Wages In February 2016, Justin Braune elected to take $11,250 of wages as common stock. The shares will formally be issued once the debt conversions and capital structure restrictions have been resolved.

Accounting Policies and Basis18

Accounting Policies and Basis of Presentation (Policies)	3 Months Ended
	Dec. 31, 2015
Accounting Policies and Basis of Presentation [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying unaudited interim consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the SEC. Certain information and disclosures normally included in the annual financial statements prepared in accordance with the accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments and disclosures necessary for a fair presentation of these consolidated financial statements have been included. Such adjustments consist of normal recurring adjustments. The current results are not an indication of the full year.
CONSOLIDATION	CONSOLIDATION The consolidated financial statements include the assets, liabilities, and operating results of the Company and its wholly-owned subsidiaries, Revival and Nouveau after elimination of all material inter-company accounts and transactions.
USE OF ESTIMATES	USE OF ESTIMATES The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions include losses for warrant contingencies and the valuation of conversion features in notes.
FAIR VALUE OF FINANCIAL INSTRUMENTS	FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Applicable accounting guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. There are three levels of inputs that may be used to measure fair value: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - Include other inputs that are directly or indirectly observable in the marketplace. Level 3 - Unobservable inputs which are supported by little or no market activity. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Derivative instruments include the warrant liability (Level 2). Derivative instruments are valued using standard calculations/models that are primarily based on observable inputs, including volatilities and interest rates. Therefore, derivative instruments are included in Level 2. Fair-value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2015 and September 30, 2015. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values. These financial instruments include cash, prepaid expenses, accounts payable, accrued liabilities, and notes payable. Fair values for these items were assumed to approximate carrying values because of their short-term nature or they are payable on demand. The following table presents the Company’s fair value hierarchy for assets measured at fair value on a recurring basis at December 31, 2015: Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents $ 47,605 $ - $ - $ 47,605 Total assets measured at fair value $ 47,605 $ - $ - $ 47,605 Liabilities Derivative instruments $ - $ 4,123 $ - $ 4,123 Total liabilities measured at fair value $ - $ 4,123 $ - $ 4,123 The following table presents the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis at September 30, 2015: Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents $ 273,904 $ - $ - $ 273,904 Total assets measured at fair value $ 273,904 $ - $ - $ 273,904 Liabilities Derivative instruments $ - $ 25,025 $ - $ 25,025 Total liabilities measured at fair value $ - $ 25,025 $ - $ 25,025
CONCENTRATION	CONCENTRATION Credit Risk At times, the Company maintains cash balances at a financial institution in excess of the FDIC insurance limit. In addition, at we extend credit to customers in the normal course of business, after we evaluate the credit worthiness. The Company does not expect to take any unnecessary credit risks causing significant write-offs of potentially uncollectible accounts. Customers Two (2) customers accounted for 80% of our accounts receivable as of December 31, 2015. One (1) customer accounted for 37% of our accounts receivable as of September 30, 2015. The loss of these customers would have a significant impact on the Company’s financial results. Suppliers Two (2) suppliers accounted for 97% of our purchases during the three months ended December 31, 2015. One (1) supplier accounted for 100% of our purchases during the three months ended December 31, 2014. The loss of these suppliers would have a significant impact on the Company’s financial results.
REVENUE RECOGNITION	REVENUE RECOGNITION The Company recognizes revenues from product sales when (a) persuasive evidence that an agreement exists; (b) the products have been delivered; (c) the prices are fixed and determinable and not subject to refund or adjustment; and (d) collection of the amounts due is reasonably assured. Revenue is generally recorded when sales orders are shipped.
INVENTORY	INVENTORY Inventory is valued at the lower of cost or market, as determined primarily by the average cost inventory method, and are stated using the first-in, first-out (FIFO) method. Management will record a provision for loss for obsolete or slow moving inventory to reduce carrying amounts to net realizable value. We purchase product sourced from China which we are required to pay 50% upon placing the order. Amounts paid for products, which have not been received, are recorded as prepaid inventory. There are no amounts paid which are in dispute or considered impaired.
FIXED ASSETS	FIXED ASSETS Fixed assets are recorded at cost and depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The estimated life of tooling related to our ceramic products is two (2) years. The estimated life of our leasehold improvements is the lesser of the term of the related lease and useful life of the asset.
IMPAIRMENT OF LONG-LIVED AND PURCHASED INTANGIBLE ASSETS	IMPAIRMENT OF LONG-LIVED AND PURCHASED INTANGIBLE ASSETS The Company has adopted Accounting Standards Codification (“ASC”) 350 “Intangibles - Goodwill and Other.” The Statement requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undercounted cash flows. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 350 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell. Long-lived assets, such as fixed assets and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the asset is measured by comparison of its carrying amount to undiscounted future net cash flows the asset is expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair market value. Estimates of expected future cash flows represent management's best estimate based on currently available information and reasonable and supportable assumptions. Any impairment recognized is permanent and may not be restored. During the three months ended December 31, 2015 and 2014, the Company did not record any impairment of its trademarks and pending patents as its expected future cash flows are in excess of their carrying amounts.
RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT Research and development costs are expensed as incurred. The costs of materials and equipment that will be acquired or constructed for research and development activities, and that have alternative future uses, both in research and development, marketing or sales, will be classified as fixed assets and depreciated over their estimated useful lives. To date, research and development costs include the research and development expenses related to prototypes of the Company’s products. During the three months ended December 31, 2015 and 2014, research and development costs were $35,599 and $51,853, respectively.
CONVERTIBLE DEBT	CONVERTIBLE DEBT Convertible debt is accounted for under the guidelines established by ASC 470-20 “Debt with Conversion and Other Options.” ASC 470-20 governs the calculation of an embedded beneficial conversion, which is treated as an additional discount to the instruments where derivative accounting (explained below) does not apply. The amount of the value of warrants and beneficial conversion feature may reduce the carrying value of the instrument to zero, but no further. The discounts relating to the initial recording of the derivatives or beneficial conversion features are accreted over the term of the debt. Many of the conversion features embedded in the Company's convertible notes are variable and are adjusted based on a discount to market prices which could cause an unlimited number of common stock to be issued. The management and board of directors currently have the ability to authorize additional shares of common stock primarily through their super voting rights under the Series A Preferred stock (See “NOTE 8 - STOCKHOLDERS’ DEFICIT”). When applicable, the Company calculates the fair value of warrants and conversion features issued with the convertible instruments using the Black-Scholes valuation method, using the same assumptions used for valuing employee options for purposes of ASC 718 “Compensation - Stock Compensation”, except that the contractual life of the warrant or conversion feature is used. Under these guidelines, the Company allocates the value of the proceeds received from a convertible debt transaction between the conversion feature and any other detachable instruments (such as warrants) on a relative fair value basis. The allocated fair value is recorded as a debt discount or premium and is amortized over the expected term of the convertible debt to interest expense. If the fair value exceeds the carrying value of the debt, an immediate charge to operations is recorded by management. Each reporting period, the Company will compute the estimated fair value of derivatives and record changes to operations. Currently no instruments are being recorded as such. The Company accounts for modifications of its BCF’s in accordance with ASC 470-50 “Modifications and Extinguishments.” ASC 470-50 requires the modification of a convertible debt instrument that changes the fair value of an embedded conversion feature and the subsequent recognition of interest expense or the associated debt instrument when the modification does not result in a debt extinguishment.
DERIVATIVE FINANCIAL INSTRUMENTS	DERIVATIVE FINANCIAL INSTRUMENTS Derivative financial instruments, as defined in ASC 815, “Accounting for Derivative Financial Instruments and Hedging Activities”, consist of financial instruments or other contracts that contain a notional amount and one or more underlying (e.g. interest rate, security price or other variable), require no initial net investment and permit net settlement. Derivative financial instruments may be free-standing or embedded in other financial instruments. Further, derivative financial instruments are initially, and subsequently, measured at fair value and recorded as liabilities or, in rare instances, assets. The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has issued financial instruments including senior convertible notes payable and freestanding stock purchase warrants with features that are either (i) not afforded equity classification, (ii) embody risks not clearly and closely related to host contracts, or (iii) may be net-cash settled by the counterparty. As required by ASC 815, in certain instances, these instruments are required to be carried as derivative liabilities, at fair value, in our consolidated financial statements. The Company estimates the fair values of derivative financial instruments using various techniques (and combinations thereof) that are considered to be consistent with objectively measuring fair values. In selecting the appropriate technique, consideration is given to, among other factors, the nature of the instrument, the market risks that it embodies and the expected means of settlement. For less complex derivative instruments, such as free-standing warrants, the Company generally uses the Black-Scholes option valuation technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fair value these instruments. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are highly volatile and sensitive to changes in the trading market price of our common stock, which has a high-historical volatility. Since derivative financial instruments are initially and subsequently carried at fair values, the Company's operating results will reflect the volatility in these estimate and assumption changes.
EARNINGS (LOSS) PER COMMON SHARE	EARNINGS (LOSS) PER COMMON SHARE Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing net income available to common shareholders by the combination of dilutive common share equivalents, comprised of shares issuable under the Company’s share-based compensation plans and the weighted-average number of common shares outstanding during the reporting period. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated, based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of an award, if any, the amount of compensation cost, if any, for future service that the Company has not yet recognized, and the estimated tax benefits that would be recorded in paid-in capital, if any, when an award is settled are assumed to be used to repurchase shares in the current period. In the event of losses, such common share equivalents are excluded as their effects are antidilutive. The following is a summary of outstanding securities that would have been included in the calculation of diluted shares outstanding since the exercise prices did not exceed the average market value of the Company’s common stock if the Company generated net income for the three months ended December, 2015: For the Three Months Ended December 31, 2015 Series A Preferred stock 500,000 Common stock options - Common stock warrants 1,184,727 Convertible notes 535,890,076 537,574,803 The following is a summary of outstanding securities which have been included in the calculation of diluted net income per share and reconciliation of net income to net income available to common stock holders for the three months ended December 31, 2014: For the Three Months Ended Weighted average common shares outstanding used in calculating basic earnings per share 10,692,552 Effect of Series A preferred stock 500,000 Effect of convertible notes payable 1,465,565 Effect of options and warrants 144,946 Weighted average common and common equivalent shares used in calculating diluted earnings per share 12,803,063 Net income as reported $ 582,910 Add - Interest on convertible notes payable 88,865 Net income available to common stockholders $ 671,775 The Company excluded 1,005,000 warrants from the computation for the three months ended December 31, 2014, as their exercise prices were in excess of the average closing market price of the Company’s common stock, causing their effects to be anti-dilutive using the treasury stock method.
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION ASC 718, “Share-Based Payment” requires that compensation cost related to share-based payment transactions be recognized in the consolidated financial statements. Share-based payment transactions within the scope of ASC 718 include stock options, restricted stock plans, performance-based awards, stock appreciation rights, and employee share purchase plans. The Company adopted ASC 718, which requires disclosure of the fair value and other characteristics of stock options and more prominent disclosure about the effects of an entity’s accounting policy decisions with respect to stock-based compensation on reported net loss. The Company has reflected the expense of such stock based compensation based on the fair value at the grant date for awards consistent with the provisions of ASC 718. In connection with the adoption of ASC 718, the fair value of our share-based compensation has been determined utilizing the Black-Scholes pricing model. The fair value of the options granted is amortized as compensation expense on a straight line basis over the requisite service period of the award, which is generally the vesting period. The fair value calculations involve significant judgments, assumptions, estimates and complexities that impact the amount of compensation expense to be recorded in current and future periods. Upon option exercise, the Company issues new shares of stock. The following weighted average variables were used in the Black Scholes model for all option issuances valued during the three months ended December 31, 2015 and 2014: Three Months Stock Price at Dividend Exercise Risk Free Volatility Average 2015 n/a n/a n/a n/a n/a n/a 2014 $ 0.73 n/a $ 0.73 2.2 % 380 % 10.0 The Company's accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of Emerging Issues Task Force (“EITF”) 96-18, “Accounting for Equity Instruments That are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services”, codified into ASC 505-50. The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor's performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement. Prepaid stock-based compensation is recorded when shares are issued based on the value on the grant date, but vest over the contractual period at which time the prorated expense will be recorded.
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS In April 2015, the FASB issued Accounting Standard Update ("ASU") 2015-03 Simplifying the Presentation of Debt Issuance Costs. This update requires capitalized debt issuance costs to be classified as a reduction to the carrying value of debt rather than a deferred charge, as is currently required. This update will be effective for the Company for all annual and interim periods beginning after December 15, 2015 and is required to be adopted retroactively for all periods presented, and early adoption is permitted. The Company will adopt the policy during the quarter ending March 31, 2016. In May 2014, the FASB issued Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers”, which supersedes most of the current revenue recognition requirements. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for these goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. This guidance is effective for the Company in the first quarter of fiscal year 2018 and early application is not permitted. Entities must adopt the new guidance using one of two retrospective application methods. The Company is currently evaluating the standard but does not expect it to have a material impact on our financial position, results of operations or cash flows. In August 2014, the FASB issued ASU 2014-15, which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued.2 An entity must provide certain disclosures if “conditions or events raise substantial doubt about the entity’s ability to continue as a going concern.” The ASU applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Financial Accounting Standards Board issues Accounting Standard Updates (“ASUs”) to amend the authoritative literature in Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of ASC. The Company believes those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on the Company.
RISKS AND UNCERTAINTIES	RISKS AND UNCERTAINTIES Although forward-looking statements in this Quarterly Report reflect our good faith judgment, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include without limitation those discussed under the heading “Risk Factors” below, as well as those discussed elsewhere in this Quarterly Report. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Quarterly Report. Readers are urged to carefully review and consider the various disclosures made in this Quarterly Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

Accounting Policies and Basis19

Accounting Policies and Basis of Presentation (Tables)	3 Months Ended
	Dec. 31, 2015
Accounting Policies and Basis of Presentation [Abstract]
Schedule of assets and liabilities measured at fair value on a recurring basis	Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents $ 47,605 $ - $ - $ 47,605 Total assets measured at fair value $ 47,605 $ - $ - $ 47,605 Liabilities Derivative instruments $ - $ 4,123 $ - $ 4,123 Total liabilities measured at fair value $ - $ 4,123 $ - $ 4,123 Level 1 Level 2 Level 3 Total Assets Cash and cash equivalents $ 273,904 $ - $ - $ 273,904 Total assets measured at fair value $ 273,904 $ - $ - $ 273,904 Liabilities Derivative instruments $ - $ 25,025 $ - $ 25,025 Total liabilities measured at fair value $ - $ 25,025 $ - $ 25,025
Schedule of securities to be included in diluted share calculation	For the Three Months December 31, 2015 Series A Preferred stock 500,000 Common stock options - Common stock warrants 1,184,727 Convertible notes 535,890,076 537,574,803
Schedule of reconcilliation of net income available to common shareholders	For the Three Months Ended Weighted average common shares outstanding used in calculating basic earnings per share 10,692,552 Effect of Series A preferred stock 500,000 Effect of convertible notes payable 1,465,565 Effect of options and warrants 144,946 Weighted average common and common equivalent shares used in calculating diluted earnings per share 12,803,063 Net income as reported $ 582,910 Add - Interest on convertible notes payable 88,865 Net income available to common stockholders $ 671,775
Schedule of weighted average variables used in Black Scholes model	Three Months Stock Price at Dividend Exercise Risk Free Volatility Average 2015 n/a n/a n/a n/a n/a n/a 2014 $ 0.73 n/a $ 0.73 2.2 % 380 % 10.0

Fixed Assets (Tables)

Fixed Assets (Tables)	3 Months Ended
	Dec. 31, 2015
Fixed Assets [Abstract]
Summary of fixed assets	December 31, September 30, Molds and Tooling $ 215,940 $ 176,015 Leasehold improvements - 29,795 Accumulated depreciation (96,302 ) (87,483 ) $ 119,638 $ 118,327

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Dec. 31, 2015
Accrued Expenses [Abstract]
Summary of accrued expenses	December 31, September 30, Accrued interest $ 82,143 $ 46,337 Accrued interest - related party 28,776 24,538 Accrued wages and taxes 79,462 112,322 Other 17,800 25,468 $ 208,181 $ 208,665

Third Party Debt (Tables)

Third Party Debt (Tables)	3 Months Ended
	Dec. 31, 2015
Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Shedule of conversions for payments	Conversion Date Principal Accrued Total Conversion Common October 8, 2015 $ 21,000 $ - $ 21,000 $ 0.012 1,818,182 October 16, 2015 18,900 - 18,900 $ 0.012 1,636,364 October 22, 2015 25,800 - 25,800 $ 0.011 2,333,786 October 29, 2015 22,460 - 22,460 $ 0.011 2,031,660 November 11, 2015 33,500 - 33,500 $ 0.007 4,649,549 November 18, 2015 24,000 - 24,000 $ 0.006 4,195,804 November 30, 2015 30,000 - 30,000 $ 0.005 5,741,627 December 11, 2015 22,000 - 22,000 $ 0.002 9,090,909 December 28, 2015 22,500 - 22,500 $ 0.002 9,297,521 $ 220,160 $ - $ 220,160 40,795,402 Conversion Date Principal Converted Accrued Interest Converted Total Converted Conversion Rate Common Shares Issued January 7, 2016 20,000 - 20,000 $ 0.002 10,101,010 January 20, 2016 12,500 - 12,500 $ 0.001 10,330,579 February 2, 2016 13,200 13,200 $ 0.001 10,909,091 $ 45,700 $ - $ 45,700 31,340,680
$2M Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Shedule of conversions for payments	Conversion Date Principal Converted Accrued Interest Converted Total Converted Conversion Rate Common Shares Issued October 1, 2015 $ 10,000 $ - $ 10,000 $ 0.0148 675,676 October 5, 2015 10,000 - 10,000 $ 0.0148 675,676 October 6, 2015 13,262 - 13,262 $ 0.0138 961,000 October 7, 2015 10,000 - 10,000 $ 0.0115 865,801 October 9, 2015 11,728 - 11,728 $ 0.0116 1,011,000 October 9, 2015 10,000 - 10,000 $ 0.0115 865,801 October 12, 2015 14,680 - 14,680 $ 0.0115 1,271,000 October 13, 2015 11,601 - 11,601 $ 0.0116 1,000,052 October 15, 2015 14,680 - 14,680 $ 0.0115 1,271,000 October 19, 2015 17,400 - 17,400 $ 0.0116 1,500,000 October 19, 2015 15,000 - 15,000 $ 0.0116 1,298,701 October 20, 2015 16,650 - 16,650 $ 0.0111 1,500,000 October 21, 2015 17,500 - 17,500 $ 0.0115 1,515,152 October 23, 2015 20,000 - 20,000 $ 0.0115 1,731,602 October 26, 2015 24,420 - 24,420 $ 0.0111 2,200,000 October 29, 2015 26,640 - 26,640 $ 0.0111 2,400,000 November 2, 2015 29,970 - 29,970 $ 0.0111 2,700,000 November 2, 2015 20,000 - 20,000 $ 0.0111 1,809,136 November 5, 2015 32,190 - 32,190 $ 0.0111 2,900,000 November 10, 2015 28,800 - 28,800 $ 0.0096 3,000,000 November 12, 2015 23,930 - 23,930 $ 0.0072 3,323,611 November 17, 2015 16,500 - 16,500 $ 0.0060 2,727,273 November 19, 2015 1,640 11,225 12,865 $ 0.0056 2,316,013 November 23, 2015 23,111 - 23,111 $ 0.0056 4,127,000 November 27, 2015 24,750 - 24,750 $ 0.0055 4,500,000 December 2, 2015 18,450 - 18,450 $ 0.0041 4,500,000 December 8, 2015 18,000 - 18,000 $ 0.0036 5,000,000 December 11, 2015 13,368 - 13,368 $ 0.0024 5,570,000 December 16, 2015 14,181 - 14,181 $ 0.0024 5,860,000 December 22, 2015 15,488 - 15,488 $ 0.0024 6,400,000 December 29, 2015 17,666 17,666 $ 0.0024 7,300,000 $ 541,604 $ 11,225 $ 552,830 82,775,494

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	3 Months Ended
	Dec. 31, 2015
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of company's warrant activity	Shares Weighted Average Weighted Average Remaining Contractual Term Aggregate Intrinsic Warrants outstanding at September 30, 2015 1,184,726 $ 0.114 0.9 $ 739,812 Warrants issued - - Warrants exercised - - Cancelled/forfeited/expired - - Warrants outstanding at December 31, 2015 1,184,726 $ 0.003 0.4 $ 18,387

Description of Business and S24

Description of Business and Summary of Significant Accounting Policies (Details) - USD ($)	Jan. 12, 2016	Dec. 10, 2015	Oct. 22, 2015	Jul. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Sep. 30, 2015	Sep. 30, 2014
Description Of Business And Summary Of Significant Accounting Policies Textuals [Abstract]
Cash					$ 47,605	$ 274,381	$ 273,904	$ 48,370
Net income					(1,126,720)	$ 582,910
Accumulated deficit					(27,737,762)		$ (26,611,042)
Restricted common stock issued, Shares			600,000
Common stock to be issued, Shares				250,000
Common stock to be issued		$ 90,000			90,000
Working capital deficit					331,421
BETTERCHEM [Member]
Description Of Business And Summary Of Significant Accounting Policies Textuals [Abstract]
Description of acquired entity				In consideration for the issuance of the shares to Dr. Scialdone, the Company acquired 80 shares of the common stock of BetterChem which represents 80% of the issued and outstanding shares of BetterChem. Dr. Scialdone retained a 20% interest in BetterChem.
Common stock to be issued, Shares				250,000
Common stock to be issued				$ 67,500
Impairment charges					$ 65,000
BETTERCHEM [Member] | Subsequent Event [Member]
Description Of Business And Summary Of Significant Accounting Policies Textuals [Abstract]
Impairment charges	$ 65,000
BETTERCHEM [Member] | Dr. Mark Scialdone [Member]
Description Of Business And Summary Of Significant Accounting Policies Textuals [Abstract]
Acquired controlling interest percentage				80.00%
Restricted common stock issued, Shares				400,000

Accounting Policies and Basis25

Accounting Policies and Basis of Presentation (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)	Dec. 31, 2015	Sep. 30, 2015
Assets
Cash and cash equivalents	$ 47,605	$ 273,904
Total assets measured at fair value	47,605	273,904
Liabilities
Derivative instruments	4,123	25,025
Total liabilities measured at fair value	4,123	25,025
Level 1 [Member]
Assets
Cash and cash equivalents	47,605	273,904
Total assets measured at fair value	$ 47,605	$ 273,904
Liabilities
Derivative instruments
Total liabilities measured at fair value
Level 2 [Member]
Assets
Cash and cash equivalents
Total assets measured at fair value
Liabilities
Derivative instruments	$ 4,123	$ 25,025
Total liabilities measured at fair value	$ 4,123	$ 25,025
Level 3 [Member]
Assets
Cash and cash equivalents
Total assets measured at fair value
Liabilities
Derivative instruments
Total liabilities measured at fair value

Accounting Policies and Basis26

Accounting Policies and Basis of Presentation (Details 1) - shares	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Weighted Average Number of Shares Outstanding, Diluted	84,039,785	12,803,063
Series A Preferred Stock [Member]
Weighted Average Number of Shares Outstanding, Diluted	500,000
Common Stock Options [Member]
Weighted Average Number of Shares Outstanding, Diluted
Common Stock Warrants [Member]
Weighted Average Number of Shares Outstanding, Diluted	1,184,727
Convertible notes [Member]
Weighted Average Number of Shares Outstanding, Diluted	535,890,076

Accounting Policies and Basis27

Accounting Policies and Basis of Presentation (Details 2) - USD ($)	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies and Basis of Presentation [Abstract]
Weighted average common shares outstanding used in calculating basic earnings per share		10,692,552
Effect of Series A preferred stock		500,000
Effect of convertible notes payable		1,465,565
Effect of options and warrants		144,946
Weighted average common and common equivalent shares used in calculating diluted earnings per share	84,039,785	12,803,063
Net income as reported	$ (1,126,720)	$ 582,910
Add - Interest on convertible notes payable		88,865
Net income available to common stockholders		$ 671,775

Accounting Policies and Basis28

Accounting Policies and Basis of Presentation (Details 3) - $ / shares	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Weighted average variables used in the Black Scholes model
Stock Price at Grant Date		$ 0.73
Dividend Yield
Exercise Price		$ 0.73
Risk Free Interest Rate		2.20%
Volatility		380.00%
Average Life		10 years

Accounting Policies and Basis29

Accounting Policies and Basis of Presentation (Details Textual)	3 Months Ended		12 Months Ended
	Dec. 31, 2015USD ($)customersuppliers	Dec. 31, 2014USD ($)shares	Sep. 30, 2015customersuppliers
Accounting policies and basis of presentation (Textual)
Inventory Related Text	We purchase product sourced from China which we are required to pay 50% upon placing the order.
Estimated useful lives	2 years
Research and development expense | $	$ 35,599	$ 51,853
Number of options excluded from the compution of diluted shares outstanding | shares		1,005,000
Customer [Member]
Accounting policies and basis of presentation (Textual)
Number of customers | customer	2		1
Credit risk rate	80.00%		37.00%
Suppliers [Member]
Accounting policies and basis of presentation (Textual)
Number of suppliers | suppliers	2		1
Credit risk rate	97.00%		100.00%

Fixed Assets (Details)

Fixed Assets (Details) - USD ($)	Dec. 31, 2015	Sep. 30, 2015
Fixed Assets [Abstract]
Molds and Tooling	$ 215,940	$ 176,015
Leasehold improvements		29,795
Accumulated depreciation	$ (96,302)	(87,483)
Fixed assets, net	$ 119,638	$ 118,327

Fixed Assets (Details Textual)

Fixed Assets (Details Textual) - USD ($)	3 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Fixed Assets [Abstract]
Depreciation	$ 38,614	$ 13,495

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Dec. 31, 2015	Sep. 30, 2015
Summary of Accrued Expenses:
Accrued interest	$ 82,143	$ 46,337
Accrued interest - related party	28,776	24,538
Accrued wages and taxes	79,462	112,322
Other	17,800	25,468
Accrued expenses	$ 208,181	$ 208,665

Accrued Expenses (Details Textu

Accrued Expenses (Details Textuals) - USD ($)	Dec. 31, 2015	Sep. 30, 2015
Accrued Expenses (Textual)
Accrued Wages And Taxes	$ 79,462	$ 112,322
Kyle Tracey [Member]
Accrued Expenses (Textual)
Accrued Wages And Taxes	25,000
Joe Andreae [Member]
Accrued Expenses (Textual)
Accrued Wages And Taxes	16,667
Allan Viernes [Member]
Accrued Expenses (Textual)
Accrued Wages And Taxes	5,000
Mike Cook [Member]
Accrued Expenses (Textual)
Accrued Wages And Taxes	10,000
Benjamin Beaulieu [Member]
Accrued Expenses (Textual)
Accrued Wages And Taxes	$ 5,000

Third Party Debt (Details)

Third Party Debt (Details) - USD ($)	Mar. 12, 2015	Dec. 31, 2015	Dec. 03, 2014
Debt Instrument [Line Items]
Principal Converted		$ 300,000
Total Converted	$ 20,000
Common Shares Issued	40,000	90,000
Securities purchase agreement [Member]
Debt Instrument [Line Items]
Principal Converted		$ 220,160	$ 500,000
Total Converted		$ 220,160
Common Shares Issued		40,795,402
Accrued Interest Converted
Conversion Rate
Securities purchase agreement [Member] | October 8, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 21,000
Total Converted		$ 21,000
Common Shares Issued		1,818,182
Accrued Interest Converted
Conversion Rate		$ 0.012
Securities purchase agreement [Member] | October 16, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 18,900
Total Converted		$ 18,900
Common Shares Issued		1,636,364
Accrued Interest Converted
Conversion Rate		$ 0.012
Securities purchase agreement [Member] | October 22, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 25,800
Total Converted		$ 25,800
Common Shares Issued		2,333,786
Accrued Interest Converted
Conversion Rate		$ 0.011
Securities purchase agreement [Member] | October 29, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 22,460
Total Converted		$ 22,460
Common Shares Issued		2,031,660
Accrued Interest Converted
Conversion Rate		$ 0.011
Securities purchase agreement [Member] | November 11, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 33,500
Total Converted		$ 33,500
Common Shares Issued		4,649,549
Accrued Interest Converted
Conversion Rate		$ 0.007
Securities purchase agreement [Member] | November 18, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 24,000
Total Converted		$ 24,000
Common Shares Issued		4,195,804
Accrued Interest Converted
Conversion Rate		$ 0.006
Securities purchase agreement [Member] | November 30, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 30,000
Total Converted		$ 30,000
Common Shares Issued		5,741,627
Accrued Interest Converted
Conversion Rate		$ 0.005
Securities purchase agreement [Member] | December 11, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 22,000
Total Converted		$ 22,000
Common Shares Issued		9,090,909
Accrued Interest Converted
Conversion Rate		$ 0.002
Securities purchase agreement [Member] | December 28, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 22,500
Total Converted		$ 22,500
Common Shares Issued		9,297,521
Accrued Interest Converted
Conversion Rate		$ 0.002
Securities purchase agreement [Member] | January 7, 2016 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 20,000
Total Converted		$ 20,000
Common Shares Issued		10,101,010
Accrued Interest Converted
Conversion Rate		$ 0.002
Securities purchase agreement [Member] | January 20, 2016 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 12,500
Total Converted		$ 12,500
Common Shares Issued		10,330,579
Accrued Interest Converted
Conversion Rate		$ 0.001
Securities purchase agreement [Member] | February 2, 2016 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 13,200,000
Total Converted		$ 13,200
Common Shares Issued		10,909,091
Accrued Interest Converted
Conversion Rate		$ 0.001
Securities Purchase Agreement Two [Member]
Debt Instrument [Line Items]
Principal Converted		$ 45,700
Total Converted		$ 45,700
Common Shares Issued		31,340,680
Accrued Interest Converted

Third Party Debt (Details 1)

Third Party Debt (Details 1) - USD ($)	Mar. 12, 2015	Dec. 31, 2015	Aug. 13, 2015
Debt Instrument [Line Items]
Principal Converted		$ 300,000
Total Converted	$ 20,000
Common Shares Issued	40,000	90,000
$2M Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Principal Converted		$ 541,604	$ 2,000,000
Total Converted		$ 552,830
Common Shares Issued		82,775,494
Accrued Interest Converted		$ 11,225
$2M Securities Purchase Agreement [Member] | October 1, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		10,000
Total Converted		$ 10,000
Common Shares Issued		675,676
Accrued Interest Converted
Conversion Rate		$ 0.0148
$2M Securities Purchase Agreement [Member] | October 5, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 10,000
Total Converted		$ 10,000
Common Shares Issued		675,676
Accrued Interest Converted
Conversion Rate		$ 0.0148
$2M Securities Purchase Agreement [Member] | October 6, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 13,262
Total Converted		$ 13,262
Common Shares Issued		961,000
Accrued Interest Converted
Conversion Rate		$ 0.0138
$2M Securities Purchase Agreement [Member] | October 7, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 10,000
Total Converted		$ 10,000
Common Shares Issued		865,801
Accrued Interest Converted
Conversion Rate		$ 0.0115
$2M Securities Purchase Agreement [Member] | October 9, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 11,728
Total Converted		$ 11,728
Common Shares Issued		1,011,000
Accrued Interest Converted
Conversion Rate		$ 0.0116
$2M Securities Purchase Agreement [Member] | October 9, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 10,000
Total Converted		$ 10,000
Common Shares Issued		865,801
Accrued Interest Converted
Conversion Rate		$ 0.0115
$2M Securities Purchase Agreement [Member] | October 12, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 14,680
Total Converted		$ 14,680
Common Shares Issued		1,271,000
Accrued Interest Converted
Conversion Rate		$ 0.0115
$2M Securities Purchase Agreement [Member] | October 13, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 11,601
Total Converted		$ 11,601
Common Shares Issued		1,000,052
Accrued Interest Converted
Conversion Rate		$ 0.0116
$2M Securities Purchase Agreement [Member] | October 15, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 14,680
Total Converted		$ 14,680
Common Shares Issued		1,271,000
Accrued Interest Converted
Conversion Rate		$ 0.0115
$2M Securities Purchase Agreement [Member] | October 19, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 17,400
Total Converted		$ 17,400
Common Shares Issued		1,500,000
Accrued Interest Converted
Conversion Rate		$ 0.0116
$2M Securities Purchase Agreement [Member] | October 19, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 15,000
Total Converted		$ 15,000
Common Shares Issued		1,298,701
Accrued Interest Converted
Conversion Rate		$ 0.0116
$2M Securities Purchase Agreement [Member] | October 20, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 16,650
Total Converted		$ 16,650
Common Shares Issued		1,500,000
Accrued Interest Converted
Conversion Rate		$ 0.0111
$2M Securities Purchase Agreement [Member] | October 21, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 17,500
Total Converted		$ 17,500
Common Shares Issued		1,515,152
Accrued Interest Converted
Conversion Rate		$ 0.0115
$2M Securities Purchase Agreement [Member] | October 23, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 20,000
Total Converted		$ 20,000
Common Shares Issued		1,731,602
Accrued Interest Converted
Conversion Rate		$ 0.0115
$2M Securities Purchase Agreement [Member] | October 26, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 24,420
Total Converted		$ 24,420
Common Shares Issued		2,200,000
Accrued Interest Converted
Conversion Rate		$ 0.0111
$2M Securities Purchase Agreement [Member] | October 29, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 26,640
Total Converted		$ 26,640
Common Shares Issued		2,400,000
Accrued Interest Converted
Conversion Rate		$ 0.0111
$2M Securities Purchase Agreement [Member] | November 2, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 29,970
Total Converted		$ 29,970
Common Shares Issued		2,700,000
Accrued Interest Converted
Conversion Rate		$ 0.0111
$2M Securities Purchase Agreement [Member] | November 2, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 20,000
Total Converted		$ 20,000
Common Shares Issued		1,809,136
Accrued Interest Converted
Conversion Rate		$ 0.0111
$2M Securities Purchase Agreement [Member] | November 5, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 32,190
Total Converted		$ 32,190
Common Shares Issued		2,900,000
Accrued Interest Converted
Conversion Rate		$ 0.0111
$2M Securities Purchase Agreement [Member] | November 10, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 28,800
Total Converted		$ 28,800
Common Shares Issued		3,000,000
Accrued Interest Converted
Conversion Rate		$ 0.0096
$2M Securities Purchase Agreement [Member] | November 12, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 23,930
Total Converted		$ 23,930
Common Shares Issued		3,323,611
Accrued Interest Converted
Conversion Rate		$ 0.0072
$2M Securities Purchase Agreement [Member] | November 17, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 16,500
Total Converted		$ 16,500
Common Shares Issued		2,727,273
Accrued Interest Converted
Conversion Rate		$ 0.0060
$2M Securities Purchase Agreement [Member] | November 19, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 1,640
Total Converted		$ 12,865
Common Shares Issued		2,316,013
Accrued Interest Converted		$ 11,225
Conversion Rate		$ 0.0056
$2M Securities Purchase Agreement [Member] | November 23, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 23,111
Total Converted		$ 23,111
Common Shares Issued		4,127,000
Accrued Interest Converted
Conversion Rate		$ 0.0056
$2M Securities Purchase Agreement [Member] | November 27, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 24,750
Total Converted		$ 24,750
Common Shares Issued		4,500,000
Accrued Interest Converted
Conversion Rate		$ 0.0055
$2M Securities Purchase Agreement [Member] | December 2, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 18,450
Total Converted		$ 18,450
Common Shares Issued		4,500,000
Accrued Interest Converted
Conversion Rate		$ 0.0041
$2M Securities Purchase Agreement [Member] | December 8, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 18,000
Total Converted		$ 18,000
Common Shares Issued		5,000,000
Accrued Interest Converted
Conversion Rate		$ 0.0036
$2M Securities Purchase Agreement [Member] | December 11, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 13,368
Total Converted		$ 13,368
Common Shares Issued		5,570,000
Accrued Interest Converted
Conversion Rate		$ 0.0024
$2M Securities Purchase Agreement [Member] | December 16, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 14,181
Total Converted		$ 14,181
Common Shares Issued		5,860,000
Accrued Interest Converted
Conversion Rate		$ 0.0024
$2M Securities Purchase Agreement [Member] | December 22, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 15,488
Total Converted		$ 15,488
Common Shares Issued		6,400,000
Accrued Interest Converted
Conversion Rate		$ 0.0024
$2M Securities Purchase Agreement [Member] | December 29, 2015 [Member]
Debt Instrument [Line Items]
Principal Converted		$ 17,666
Total Converted		$ 17,666
Common Shares Issued		7,300,000
Accrued Interest Converted
Conversion Rate		$ 0.0024

Third Party Debt (Details Textu

Third Party Debt (Details Textual)	Dec. 15, 2015USD ($)	Dec. 14, 2015USD ($)shares	Dec. 10, 2015USD ($)	Aug. 13, 2015USD ($)	Aug. 12, 2015USD ($)	Aug. 05, 2015USD ($)	Mar. 12, 2015USD ($)$ / sharesshares	Feb. 10, 2015USD ($)$ / shares	Dec. 03, 2014USD ($)$ / shares	Feb. 11, 2014USD ($)Investors$ / shares	Jul. 31, 2015shares	Feb. 18, 2014shares	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)
Third Party Debt (Textual)
Unamortized discount convertible notes payable, current													$ 375,518		$ 369,569
Unamortized discount convertible notes payable, non current													19,159		507,360
Aggregate principal amount													300,000
Interest rate											80.00%
Amortized discount to interest expense													1,500
Discount related to beneficial conversion feature													60,900
Original issue discount													5,000
Accrued interest													3,290
Common stock to be issued, Shares | shares											250,000
Proceeds from initial investor													2,147
Interest expense													710,552	$ 77,990
Deferred financing costs													$ 85,495		107,908
Deferred financing costs, long-term															12,067
Net proceeds													$ 50,000
Convertible notes payable, current													594,873		305,923
Convertible notes payable, long-term													26,541		458,404
Total unamortized discounts													$ 29,541
Common stock convertion amount							$ 20,000
Common stock convertion shares | shares							40,000						90,000
Convertible note principal amount			$ 105,000
Beneficial conversion feature recorded with convertible notes payable													$ 36,960	$ 168,000
Proceeds from original convertible note													46,000	475,000
Accredited Investor [Member]
Third Party Debt (Textual)
Amortized discount to interest expense													1,540
Unamortized discount													35,420
Interest expense	$ 11,600
Deferred financing costs													3,833
Amortization of interest expense													167
Term of note	2 years
Issuance of deferred costs													4,000
Proceeds from original convertible note	$ 50,000
Securities Purchase Agreement [Member]
Third Party Debt (Textual)
Original issue discount of note													50,000
Aggregate principal amount									$ 500,000				220,160
Amortized discount to interest expense													12,162	2,778
Original issue discount									50,000
Transaction expenses									10,000
Finder's fee									25,000
Deferred financing costs													45,940
Net proceeds									475,000
Amortization of interest expense													7,657	$ 2,552
Common stock convertion amount													$ 220,160
Common stock convertion shares | shares													40,795,402
Unsecured convertible promissory note principal amount									$ 560,000
Loss on debt extinguishment													$ 158,916
$2M Securities Purchase Agreement [Member]
Third Party Debt (Textual)
Original issue discount of note															148,600
Unamortized discount convertible notes payable, current													25,445
Aggregate principal amount				$ 2,000,000									541,604
Interest rate								10.00%
Conversion price | $ / shares								$ 0.50
Amortized discount to interest expense													28,121		94,131
Unamortized discount													3,079
Discount related to beneficial conversion feature													108,641		108,641
Original issue discount								$ 182,000
Convertible notes payable								1,808,000
Conversion description				The conversion rate of the note was amended to 55% of the lowest price of the prior fifteen (15) trading days and conversion floor removed which amendment was triggered by the dilutive issuances of the August 2015 convertible note financing thereby entitling Investor to the lowest conversion rate granted during the year ended September 30, 2015 per the terms of the Securities Purchase Agreement.
Accrued interest													42,867
Interest expense													4,781
Loss on debt in unamortized discount															385,815
Transaction expenses								$ 10,000
Value of note issued															800,000
Net proceeds															651,395
Amortization of interest expense															45,600
Convertible note, New discount															440,000
Total unamortized discounts															108,641
Percentage of premium amount								25.00%
Percentage of conversion price								70.00%
Common stock convertion amount													$ 552,830
Common stock convertion shares | shares													82,775,494
Unsecured convertible promissory note principal amount								$ 2,000,000
Minimum [Member] | $2M Securities Purchase Agreement [Member]
Third Party Debt (Textual)
Aggregate principal amount				$ 800,000											$ 800,000
6% Convertible Notes [Member]
Third Party Debt (Textual)
Converted shares outstanding							$ 30,000
Aggregate principal amount										$ 230,000
Interest rate										6.00%					6.00%
Amortized discount to interest expense															$ 32,333	$ 57,667
Discount related to beneficial conversion feature										$ 92,000
Convertible notes payable							$ 17,200
Conversion description										The conversion price of these 6% Notes is the average of the fifteen (15) lowest daily VWAP's occurring during the twenty (20) consecutive trading days immediately preceding the date each Holder elects convert all of their 6% Note minus a discount of 40%.
Accrued interest		$ 1,351
Common stock to be issued, Shares | shares		13,063,013
Proceeds from initial investor															800,000
Percentage of note outstanding							6.00%
Fair value of loss on debt							$ 23,443
Common stock convertion amount		$ 30,000					$ 80,000
Common stock convertion shares | shares							160,000
Number of accredited investors | Investors										10
6% Convertible Notes [Member] | Minimum [Member]
Third Party Debt (Textual)
Maturity date										Feb. 28, 2015
Conversion price | $ / shares							$ 0.50			$ 1
6% Convertible Notes [Member] | Maximum [Member]
Third Party Debt (Textual)
Maturity date										Mar. 31, 2015
Conversion price | $ / shares							$ 1			$ 3
10% Convertible Notes [Member] | Securities Purchase Agreement [Member]
Third Party Debt (Textual)
Interest rate									10.00%
Conversion price | $ / shares									$ 0.50
Amortized discount to interest expense													$ 116,332
Discount related to beneficial conversion feature									$ 168,000
Original issue discount													242,916
Conversion description									The Note bears interest at the rate of 10% per annum and is convertible into common stock of the Company at a conversion price per share of 70% of the average of the three (3) lowest Closing Sale Prices in the ten (10) Trading Days immediately preceding the applicable Conversion (subject to adjustment in the event of stock splits, stock dividends, and similar transactions, and in the event of subsequent sales of common stock at a lower purchase price (subject to certain exceptions))(the "Conversion Price"). In no event will the Conversion Price be less than $0.50 per share.
Repayment of debt description									Repayment of principal on the Note, together with accrued interest thereon, is due in twelve monthly installments, commencing six months from issuance. The Company may make such payments in cash (in which event the Company will pay a 25% premium) or, subject to certain conditions, in shares of common stock valued at the lower of the Conversion Price or 70% of the average of the three (3) lowest Closing Sale Prices in the ten (10) Trading Days immediately preceding the applicable payment date.
Deferred financing costs													12,761
Amortization of interest expense													168,000
8% Convertible Note [Member]
Third Party Debt (Textual)
Common stock convertion shares | shares												42,370
Convertible Note [Member]
Third Party Debt (Textual)
Unamortized discount convertible notes payable, current													87,121
Unamortized discount convertible notes payable, non current													19,159
Accrued interest															18,541
Interest expense															$ 8,596
Convertible notes payable, current													120,684
Convertible notes payable, long-term													26,541
Convertible Note Financing [Member]
Third Party Debt (Textual)
Original issue discount of note													1,563
Aggregate principal amount					$ 105,000
Maturity date					Jun. 12, 2016
Interest rate					8.00%
Discount related to beneficial conversion feature													253,617
Original issue discount													12,500
Conversion description					The convertible note bears interest at the rate of 8% per annum and is convertible into common stock of the Company at any time after 180 days from issuance of the note at a conversion price per share equal to 58% of the average of the lowest trading price of the common stock in the thirteen (13) trading days immediately preceding the applicable conversion date. The Company has the option to prepay the convertible note in the first 180 days from closing subject to a prepayment penalty of 150% of principal plus interest.
Accrued interest													17,444
Interest expense													9,057
Net proceeds													18,270
Amortization of interest expense													$ 73,025
Percentage of conversion price					150.00%
Certain fees						$ 541,000

Related Party Debt (Details)

Related Party Debt (Details) - USD ($)	Dec. 10, 2015	Dec. 07, 2013	Dec. 31, 2015	Sep. 30, 2015	Nov. 27, 2013	Sep. 30, 2013
Related Party Debt (Textual)
Accrued interest			$ 82,143	$ 46,337
Preferred stock, shares authorized					100,000,000
Shareholder [Member]
Related Party Debt (Textual)
Accounts payable, related parties						$ 15,000
Accrued interest			1,875
Interest expense related to notes payable			230
Interest rate		6.00%
Maturity date		Dec. 1, 2016
Series B Preferred Stock [Member]
Related Party Debt (Textual)
Accrued interest			$ 26,902
Interest rate	8.00%
Term of convertible note	1 year
Common stock conversion basis	Series B Preferred Stock on a one-for-one (1:1) basis into shares of common stock of the Company at a fixed price per share of $0.01.
Common stock fixed price per share	$ 0.01
Preferred stock, shares authorized	30,000,000		30,000,000	30,000,000
Voting rights, description	Each share of Series B shall be entitled to five (5) votes for every one (1) vote entitled to each share of Common Stock.
Aggregate principal amount	$ 300,000		$ 300,000
Equity investment by the investor, description	1) $50,000 from Hive Ceramics, LLC in new capital to the Company and 2) an amended and restated note for Hive Ceramics LLC in the amount of $250,000 for capital previously contributed which is soon to be due and payable.

Commitments and Contingencies (

Commitments and Contingencies (Details)	Dec. 10, 2015USD ($)shares	May. 01, 2015USD ($)	Dec. 15, 2014USD ($)	Jan. 31, 2015shares	Dec. 31, 2015USD ($)ft²shares	Dec. 31, 2014USD ($)	Mar. 31, 2014USD ($)$ / sharesshares	Oct. 22, 2015$ / shares	Sep. 30, 2015USD ($)shares
Other Commitments [Line Items]
Company leases for office | ft²					2,500
Leases rent expense					$ 2,500
Gain on change in warrant liability					$ (20,902)	$ (1,409,825)
Proceeds from Legal Settlements						62,930
Warrant liability					$ 4,123				$ 25,025
Vendor credits on settlement						200,000
Lease expiration date					Dec. 31, 2017
Total vendor credits on settlement						325,000
Treasury Stock, Shares | shares					1,025,625				690,625
Treasury Stock, Value					$ 440,101				$ 435,031
Gain (Loss) Related to Litigation Settlement						$ 257,930
Shares issued, price per share | $ / shares								$ 0.024
Justin Braune [Member]
Other Commitments [Line Items]
Annual salary	$ 150,000
Sales based compensation, description	Bi-monthly sales-based compensation of $1.00 USD per unit of wholesale sales of Mr. Braune's new vaporizer pen product line and $3.00 USD per unit on retail sales.
Common stock issued as compensation | shares	20,000,000
Description of employment agreement	The Employment Agreement continues until terminated by either party upon 30 days' prior written notice.
Fair value of the stock vested issuance					$ 100,000
Justin Braune [Member] | June 10, 2015 [Member]
Other Commitments [Line Items]
Common stock shares vested	$ 5,000,000
Justin Braune [Member] | June 10, 2016 [Member]
Other Commitments [Line Items]
Common stock shares vested	5,000,000
Justin Braune [Member] | December 10, 2016 [Member]
Other Commitments [Line Items]
Common stock shares vested	$ 5,000,000
Chief Science Officer [Member]
Other Commitments [Line Items]
Term of executive employment agreement		2 years
Annual salary		$ 102,000
Shareholders and Related Parties [Member]
Other Commitments [Line Items]
Gain (Loss) Related to Litigation Settlement			$ 257,930
Officer [Member]
Other Commitments [Line Items]
Shares assigned to officers | shares				440,625
Treasury Stock, Shares | shares					440,625
Treasury Stock, Value					$ 367,531
Warrant [Member]
Other Commitments [Line Items]
Loss on settlement of warrants							$ 29,528,844
Long term warrant liability							$ 29,430,022
Closing stock shares | shares							4,407,200
Fair value of warrant liability					1,184,727
Warrant liability					$ 4,123
Shares issued, price per share | $ / shares							$ 7.25
Warrant [Member] | Minimum [Member]
Other Commitments [Line Items]
Shares issued, price per share | $ / shares							4.72
Warrant [Member] | Maximum [Member]
Other Commitments [Line Items]
Shares issued, price per share | $ / shares							$ 7.25

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - Warrant [Member]	3 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
WARRANTS
Warrants outstanding, Shares, Beginning balance | shares	1,184,726
Warrants issued | shares
Warrants exercised | shares
Warrants cancelled/forfeited/expired | shares
Warrants outstanding, Shares, Ending Balance | shares	1,184,726
Warrants Weighted Average Price, Beginning balance | $ / shares	$ 0.114
Warrants issued/granted, Weighted Average Price | $ / shares
Warrants exercised, Weighted Exercise Price | $ / shares
Warrants Cancelled/forfeited/expired, Weighted Average Price | $ / shares
Warrants Weighted Average Price, Ending Balance | $ / shares	$ 0.003
Warrants outstanding, Weighted Average Remaining Contractual Term, Beginning	10 months 24 days
Warrants outstanding, Weighted Average Remaining Contractual Term, Ending	4 months 24 days
Warrants Outstanding, Aggregate Intrinsic Value, Beginning balance | $	$ 739,812
Warrants Outstanding, Aggregate Intrinsic value, Ending Balance | $	$ 18,387

Stockholders' Deficit (Details

Stockholders' Deficit (Details Textual) - USD ($)

Dec. 10, 2015

Mar. 12, 2015

Apr. 01, 2014

Dec. 23, 2015

Dec. 21, 2015

Dec. 20, 2015

Nov. 25, 2015

Oct. 22, 2015

Jul. 31, 2015

Jun. 19, 2014

Dec. 31, 2015

Dec. 31, 2014

Sep. 30, 2015

Nov. 27, 2013

Stockholders' Deficit (Textual)

Shares issued during period

250,000

Common stock, shares authorized

1,000,000,000

1,000,000,000

1,000,000,000

Preferred stock, shares authorized

100,000,000

Aggregate principal amount

$ 300,000

Common stock issued on conversion

40,000

90,000

Common stock issued for services

$ 31,689

Restricted common stock issued, Shares

600,000

Shares issued, price per share

$ 0.024

Issuance of common stock

31,689

Issuance of fair market value

50,000

Conversion of unpaid wages

93,334

Treasury Stock, Value

440,101

$ 435,031

Common stock purchased by Investor

$ 90,000

90,000

Common stock price percentage

90.00%

Selling and Marketing Expense [Member]

Stockholders' Deficit (Textual)

Fair value of the stock vested issuance

30,000

General and Administrative Expense [Member]

Stockholders' Deficit (Textual)

Fair value of the stock vested issuance

$ 1,143

$ 547

$ 36,000

Series A Preferred Stock [Member]

Stockholders' Deficit (Textual)

Shares issued during period

500,000

Preferred stock, shares authorized

100,000,000

100,000,000

Preferred stock, shares outstanding

500,000

500,000

Series B Preferred Stock [Member]

Stockholders' Deficit (Textual)

Preferred stock, shares authorized

30,000,000

30,000,000

30,000,000

Preferred stock, shares issued

Preferred stock, shares outstanding

Preferred Stock [Member]

Stockholders' Deficit (Textual)

Shares issued during period

500,000

Preferred stock, shares authorized

30,000,000

100,000,000

Convertible price, description

A one-time pro rata adjustment of up to ten-for-one (10-1) based upon the Company generating aggregate gross revenues over the two years of at least $8,000,000 (e.g. If the Company generates only $4,000,000 in aggregate gross revenues over the two year period then the convertible ratio will adjust to 5-1). In no event will the issuance convert into more than 5,000,000 shares of common stock of the Company.

Description of asset purchase agreement

Series A Shares are entitled to vote at a 15-1 ratio to Common Stock.

Allan Viernes [Member]

Stockholders' Deficit (Textual)

Restricted common stock issued, Shares

300,000

Shares issued, price per share

$ 0.024

Joe Andreae [Member]

Stockholders' Deficit (Textual)

Restricted common stock issued, Shares

130,000

Treasury Stock, Value

$ 3,120

Kyle Tracey [Member]

Stockholders' Deficit (Textual)

Restricted common stock issued, Shares

130,000

Treasury Stock, Value

$ 1,170

Board of Directors [Member]

Stockholders' Deficit (Textual)

Restricted common stock issued, Shares

142,857

49,760

1,250,000

Shares issued, price per share

$ 0.008

$ 0.011

$ 0.024

Board of Directors [Member] | Michael Cook [Member]

Stockholders' Deficit (Textual)

Restricted common stock issued, Shares

1,250,000

Shares issued, price per share

$ 0.024

Conversion of unpaid wages

$ 3,000

Board of Directors [Member] | Kyle Tracey [Member]

Stockholders' Deficit (Textual)

Restricted common stock issued, Shares

2,083,333

Shares issued, price per share

$ 0.024

Conversion of unpaid wages

$ 50,000

Board of Directors [Member] | Kyle Tracey One [Member]

Stockholders' Deficit (Textual)

Restricted common stock issued, Shares

555,555

Shares issued, price per share

$ 0.024

Conversion of unpaid wages

$ 13,333

Employees [Member]

Stockholders' Deficit (Textual)

Restricted common stock issued, Shares

30,000

Treasury Stock, Value

$ 360

Benjamin Beaulieu [Member]

Stockholders' Deficit (Textual)

Restricted common stock issued, Shares

300,000

Shares issued, price per share

$ 0.024

Benjamin Beaulieu [Member] | Allan Viernes [Member]

Stockholders' Deficit (Textual)

Restricted common stock issued, Shares

30,000

Treasury Stock, Value

$ 420

Intellectual Property (Details)

Intellectual Property (Details) - USD ($)	Dec. 31, 2015	Sep. 30, 2015
Intellectual Property (Textual)
Trademarks	$ 123,150	$ 123,150
Trademarks [Member]
Intellectual Property (Textual)
Trademarks	$ 123,150

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	1 Months Ended	3 Months Ended
	Feb. 29, 2016	Dec. 31, 2015
Subsequent Event (Textual)
Common stock issued for services		$ 31,689
Subsequent Event [Member] | Justin Braune [Member]
Subsequent Event (Textual)
Common stock issued for services	$ 11,250